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I. Kurzzusammenfassung 
Die ektope und reversible Expression von Proteinen kann das Schicksal von Zellen 
beeinflussen. Da derzeitige transiente Expressionsmethoden (z.B. physikochemische 
oder adenovirale Systeme) eine geringe Effizienz, eine zu hohe Toxizität oder uner-
wünschte, residuale Integrationen aufweisen können, ist die Entwicklung neuer und 
verbesserter Alternativen von großem Interesse. In dieser Arbeit wurde untersucht, 
ob sich modifizierte, auf dem Mausleukämievirus basierende Vektoren für die 
gezielte und transiente Zellmodifikation eignen. Wir konstruierten drei Vektor-
mutanten, die entweder in reverser Transkription (aPBS, ∆PBS) oder Integration 
(∆U5) defizient waren, und testeten sie in ihrer Fähigkeit zur transienten 
Proteinexpression. Alle drei Vektormutanten vermittelten einen effizienten und 
transienten Transfer der Rekombinase Cre in humane und murine Fibroblasten. Da 
hierbei die aPBS den anderen Mutanten überlegen war, wurde sie bevorzugt in 
dieser Arbeit verwendet. Diese Art des Cre Transfers war Rezeptor mediiert und 
erforderte die Formation von Partikeln sowie die Präsenz des retroviralen 
Verpackungssignals. Wir bezeichneten daher diese Technik als retroviralen Partikel 
mediierten mRNA Transfer (RMT).  
Die biochemische Charakterisierung von Wildtyp- und RMT-Partikeln zeigte keine 
signifikanten Unterschiede. Im Vergleich zu episomalen, lentiviralen Vektoren ver-
mittelten RMT-Partikel eine geringere und kürzeranhaltende Proteinexpression, 
wiesen jedoch keinerlei residuale Integrationen auf. In einem weiteren Schritt unter-
suchten wir die Sensitivität dieser Partikel gegenüber zellulären Restriktionsfaktoren. 
Hierbei stellte sich heraus, dass sowohl huTRIM5α als auch in einem geringeren 
Maße Fv1 in der Lage waren, RMT zu inhibieren, und dass die huTRIM5α vermittelte 
Restriktion zu einem beschleunigten Abbau retroviraler RNA-Genome führte. Die Ex-
pression von shRNAs in Zielzellen, die gegen das eindringende RNA-Genom ge-
richtet waren, hemmte RMT, deutlich zeigend, dass das retrovirale RNA-Genom die 
verantwortliche Komponente für RMT ist. Dies suggeriert ein Modell, in welchem das 
retrovirale RNA-Genom als Translationsmatrize dienen kann, wenn es nicht revers 
transkribiert wird. Die Anwendung von RMT ist daher ausichtsreich für Applikationen, 
in denen eine geringe und transiente Expression von Proteinen zu deutlichen 
biologischen Effekten führt. Desweiteren könnte RMT der Analyse von Retrovirus-
Wirt-Wechselwirkungen dienen. 
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II. Abstract 
Short-term, reversible expression of foreign proteins could be useful to modify cell 
fate. Since current transient expression methods (e.g. physicochemical or adenoviral 
systems) may suffer from low efficiency, high cytotoxicity or unwanted residual 
integration events, the development of new and improved alternatives is of great 
interest. The present study addressed the question whether modified murine 
leukemia virus-based vectors can be exploited for targeted and transient cell 
modification. Thus, three different gammaretroviral vector mutants, being either 
disabled in reverse transcription (aPBS, ∆PBS) and/or integration (∆U5), have been 
generated and tested for their capability of transient expression of recombinant 
proteins in target cells. As a paradigm, we could show that all three vector mutants 
were able to mediate transient, efficient and non-toxic delivery of Cre recombinase 
into human and mouse fibroblasts. Interestingly, the reverse transcription deficient 
aPBS mutant was superior to ∆PBS and ∆U5 mutants and therefore primarily used in 
this study. This type of Cre delivery was receptor-mediated, required particle 
assembly and depended on the presence of the packaging signal within the retroviral 
vector genome. For that reason we named this technique retroviral particle-mediated 
mRNA transfer (RMT). 
Biochemical characterization of RMT vector particles did not reveal any significant 
differences when compared to the wild-type counterpart. The comparison with non-
integrating lentiviral vectors revealed that RMT expressed foreign proteins shorter 
and at lower levels, but without the risk of residual integration events. To understand 
the mechanism of RMT, we explored the sensitivity of RMT particles to cellular 
restriction factors, targeting the incoming retroviral capsid. Both huTRIM5α and to a 
lesser extent the Friend virus susceptibility factor 1 were capable of effectively 
restricting RMT. Interestingly, huTRIM5α-mediated restriction of RMT resulted in 
reduced levels of retroviral mRNA genomes. Furthermore, cells expressing short 
hairpin RNAs targeting the retroviral genome inhibited RMT, clearly showing that the 
genomic mRNA is responsible for functional RMT. This suggests a model, in which – 
after entry - the retroviral mRNA becomes accessible to ribosomes and serves as a 
translation template if it is not undergoing reverse transcription. In conclusion, RMT is 
promising for applications in which low and transient expression of proteins achieves 
striking biological effects, and might be a useful tool to analyze retrovirus-host 
interactions early after entry before proviral DNA synthesis. 
 Schlagworte / Keywords III 
     
 
Schlagworte: 
Mausleukämievirus 
Retroviraler Lebenszyklus 
Gentherapie 
 
Keywords: 
Murine leukemia virus 
Retroviral life cycle 
Gene therapy 
 
 
 Table of contents IV 
     
III. Table of contents       
I. Kurzzusammenfassung..................................................................................................... I 
II. Abstract ............................................................................................................................ II 
III. Table of contents ...........................................................................................................IV 
IV. Table of figures..............................................................................................................VI 
V. List of abbreviations ....................................................................................................VIII 
A. Introduction ..................................................................................................................... 1 
1. Retroviruses and their replication ........................................................................... 2 
a. Overview..................................................................................................... 2 
b. The gammaretroviral genome ..................................................................... 3 
c. The expression of gammaretroviral proteins................................................ 5 
d. The gammaretroviral particle....................................................................... 7 
e. The retroviral life cycle ................................................................................ 8 
2. The retroviral vector system.................................................................................. 15 
a. The gammaretroviral vector used in this study .......................................... 16 
b. Non-integrating retroviral vectors .............................................................. 17 
3. Retroviral restriction factors .................................................................................. 19 
a. The restriction factor Fv1........................................................................... 20 
b. The tripartite motif TRIM5α........................................................................ 21 
B. General aim of the study............................................................................................... 25 
C. Publication 1.................................................................................................................. 27 
Retroviral Pseudotransduction for Targeted Cell Manipulation ................................. 27 
a. Abstract..................................................................................................... 29 
b. Introduction ............................................................................................... 30 
c. Results ...................................................................................................... 30 
d. Discussion................................................................................................. 37 
e. Experimental Procedures .......................................................................... 40 
f. References................................................................................................. 43 
g. Supplementary Figures ............................................................................. 45 
D. Publication 2.................................................................................................................. 49 
Cellular Restriction of Retrovirus Particle-Mediated mRNA Transfer ........................ 49 
a. Abstract..................................................................................................... 51 
b. Introduction ............................................................................................... 52 
c. Results ...................................................................................................... 53 
d. Discussion................................................................................................. 64 
e. Materials and Methods .............................................................................. 66 
f. References................................................................................................. 71 
E. Publication 3 .................................................................................................................. 74 
Overcoming Promoter Competition in Packaging Cells Improves Production of Self-
Inactivating Retroviral Vectors ............................................................................. 74 
a. Abstract..................................................................................................... 76 
b. Introduction ............................................................................................... 77 
c. Results ...................................................................................................... 78 
d. Discussion................................................................................................. 87 
e. Materials and Methods .............................................................................. 89 
f. References................................................................................................. 95 
g. Supplementary Figures ............................................................................. 98 
F. Discussion & Outlook.................................................................................................... 99 
1. RMT in comparison to current transient expression methods: Advantages and 
limitations........................................................................................................... 101 
2. What makes the aPBS mutant superior to the ∆PBS and ∆U5 mutants?............ 104 
3. Translation or reverse transcription? Two potential pathways for retroviral mRNAs 
after cell entry .................................................................................................... 106 
4. By-product or necessity? Biological purpose of RMT for the retroviral life cycle.. 108 
5. Do eukaryotic translation initiation factors assist during reverse transcription? ... 109 
 Table of contents V 
     
6. The inhibition of RMT via endogenously expressed human TRIM5α is caused by 
mRNA degradation ............................................................................................ 111 
7. Outlook and implications for future applications.................................................. 114 
G. Appendix ..................................................................................................................... 118 
1. References (other than mentioned in publications) ............................................. 118 
2. List of own publications....................................................................................... 130 
3. Curriculum vitae.................................................................................................. 131 
4. Danksagung ....................................................................................................... 132 
5. Erklärung zur Dissertation .................................................................................. 133 
  
 
 Table of figures  VI 
     
IV. Table of figures 
Figure Title Page 
 
Introduction 
 
1 The gammaretroviral RNA genome and its conversion into proviral 
DNA 
4 
2 The gammaretroviral transcripts 5 
3 The gammaretroviral virion 7 
4 The gammaretroviral life cycle 8 
5 The process of reverse transcription 10 
6 From replication competent gammaretroviruses to gammaretroviral 
vector systems 
16 
7 The basic gammaretroviral vector plasmid used in this study 17 
8 Scheme of the HIV-1 integrase 19 
9 Schematical illustration of the TRIM5α protein 23 
 
Publication 1 
 
1 Retroviral vector mutants used for pseudotransduction experi-
ments, expressing either nlsCre or EGFP 
32 
2 Cre expression mediated by pseudotransduction is dose-depen-
dent and avoids toxic side effects 
33 
3 Counterselection of cells constitutively expressing nlsCre 35 
4 Pseudotransduction is receptor-mediated and allows targeting of 
distinct cells in a mixed population 
37 
Suppl. Fig. 1 Cre activity mediates a switch from red to green fluorescence in 
SC-1 cells containing the Cre reporter allele SFr-2 
45 
Suppl. Fig. 2 Pseudotransduction of Cre is superior to adenoviral or physico-
chemical DNA delivery 
46 
Suppl. Fig. 3 The nucleoside analog 3´-Azido-3´-deoxythymidine (AZT) does not 
inhibit retroviral pseudotransfer, while strongly inhibiting stable re-
troviral gene transfer 
47 
Suppl. Fig. 4 Proposed “early translation” of retroviral mRNA in the retroviral life 
cycle 
48 
 
Publication 2 
 
1 Comparison of RMT using integrase-deficient lentiviral particles 
and integrating gammaretroviral and lentiviral particles 
54 
2 Capsid Western blot of viral supernatants of iRV and RMT vectors 57 
3 RMT is susceptible to ectopically expressed shRNAs 58 
4 RMT is susceptible to TRIM5α restriction but can be rescued by the 
inhibition of proteasomes 
60 
5 RT-competent and RMT particles are sensitive to Fv1 restriction 62 
6 Retroviral genomic RNA and capsid levels of restricted and non-
restricted particles from 2 to 8 h postinfection 
63 
 
Publication 3 
 
1 Gammaretroviral SIN vectors show lower titers compared to LTR-
driven counterparts 
79 
2 Presence of the RSV promoter in the 5´LTR leads to a substantial 
titer increase 
81 
3 Performance of the new SIN vector in primary rhesus CD34+ cells 83 
4 Dual fluorescent vectors as a tool to analyze promoter competition 85 
5 A tetracycline-inducible promoter allows high-titer gammaretroviral 
SIN vector production 
87 
Suppl. Fig. 1 The RSV promoter enhances particle-mediated mRNA transfer 98 
  
 
  
 
 Table of figures  VII 
     
  
 
 
Discussion 
 
10 The RNA content of retroviral supernatants correlates with the 
biological titer 
100 
11 The proposed “early translation” of retroviral vector genomes 
shortly after entry 
102 
12 The initiation of translation in eukaryotes 111 
13 Human TRIM5α-mediated restriction of RMT: A proposed model 114 
 List of abbreviations VIII 
     
V. List of abbreviations 
aPBS Artificial primer binding site 
APOBEC Apolipoprotein B mRNA-editing enzyme catalytic protein 
ASV Avian sarcoma virus 
att Integrase attachment site 
AZT Azidodeoxythymidine  
BAF-1 Barrier to auto-integration factor-1 
bp Base pairs 
CA Capsid protein, retroviral protein 
cDNA Complementary DNA, complementary to mRNA 
CMV Cytomegalovirus 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide tri-phosphate 
Cre Site-specific recombinase Cre 
C-terminal Carboxy-terminal 
ECL Enhanced chemiluminescence 
Eco Ecotropic, MLV glycoprotein 
EGFP Enhanced green fluorescence protein 
eIF Eukaryotic initiation factor  
eRF1 Eukaryotic release factor 1 
Env Envelope, retroviral glycoproteins 
FACS Fluorescence activated cell sorter / sorting 
FSC Forward scatter 
FCS Fetal calf serum 
Fv1 Friend virus susceptibility factor 1 
Gag Group specific antigen, retroviral structural proteins 
GFP Green fluorescent protein 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
HRP Horse radish peroxidase 
huTRIM5α Human tripartite motif 5α 
IN Integrase, retroviral protein 
IRES Internal ribosomal entry site 
kb Kilo bases 
kDa Kilo Dalton 
LAP2α Lamina-associated polypeptide 2α 
LTR Long terminal repeat 
MA Matrix, retroviral protein 
MESV Murine embryonic stem cell virus 
MG132 Proteasomal inhibitor 
MHC Major histocompatibility complex 
miRNA Micro RNA 
MOI Multiplicity of infection 
MoMLV Moloney murine leukemia virus 
MPSV Myeloproliferative sarcoma virus 
mRNA Messenger RNA 
MLV Murine leukemia virus 
MVB Multivesicular body 
NC Nucleocapsid, retroviral protein  
nlsCre Cre recombinase containing a nucear localization signal 
nt Nucleotides 
N-terminal Amino-terminal 
OH-group Hydroxyl-group 
ORF Open reading frame 
PABP PolyA binding protein  
PBS Primer binding site 
 List of abbreviations IX 
     
PCR Polymerase chain reaction 
PIC Preintegration complex 
Pol Polymerase, retroviral enzymatics proteins 
PPT Polypurine tract 
PR Protease 
RBCC motif RING-Bbox-coiled-coil motif 
RCR Replication competent retrovirus 
RD114 Envelope protein of feline endogenous retrovirus 
rER Rough endoplasmic reticulum 
rhTRIM5α Rhesus macaque tripartite motif 5α 
RING Really interesting new gene, N-terminal domain of TRIM5 proteins 
RMT Retroviral particle-mediated mRNA transfer 
RNA Ribonucleic acid 
RNase H Ribonuclease H, subunit of the reverse transcriptase 
rpm Rounds per minute 
R-region Redundant region 
RSV Rous sarcoma virus  
RT Reverse transcriptase 
RTC Reverse transcription complex 
SA Splice acceptor 
SD Splice donor 
SFFV Spleen focus-forming virus 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
SIV Simian immunodeficiency virus 
SSC Side scatter 
SU Surface subunit 
TM Transmembrane subunit 
TRIM Tripartite motif 
tRNA Transfer ribonucleic acid 
U Units 
UTR Untranslated region 
Vif Viral infectivity factor, HIV-1 protein 
VSV-G Glycoprotein of vesicular stomatitis virus 
WHV Woodchuck hepatitis virus 
wPRE Woodchuck posttranscriptional regulatory element 
Wt Wild-type 
Ψ Retroviral packaging signal 
ZAP Zinc finger antiviral protein 
 
 
 
AMINO ACIDS 
A Ala Alanine M Met Methionine 
C Cys Cysteine N Asn Asparagine 
D Asp Aspartic acid P Pro Proline 
E Glu Glutamic acid Q Gln Glutamine 
F Phe Phenylalanine R Arg Arginine 
G Gly Glycine S Ser Serine 
H His Histidine T Thr Threonine 
I Ile Isoleucine V Val Valine 
K Lys Lysine W Trp Tryptophan 
L Leu Leucine Y Tyr Tyrosine 
  Introduction    1   
     
A. Introduction 
Targeted and controlled manipulation of cells is widely used in order to better 
understand the role and functional relevance of cellular proteins in cellular processes. 
The ectopic expression or down-regulation (by RNA interference, including short 
hairpin RNAs (shRNAs) or micro RNAs (miRNAs)) of selected proteins helps to 
elucidate the complex biochemical processes in a given cell. Currently, there are 
several techniques available for the specific manipulation of cells. A general 
distinction is made between the transfer of nucleic acids (DNA or RNA transfection, 
and viral gene transfer) and the transfer of proteins (e.g. transduction of 
recombinantly produced proteins) into target cells. Since protein transduction is a 
relatively young technology and still has strong limitations, the transfer of nucleic 
acids by appropriate vector systems is preferably used. Vectors consist of nucleic 
acid molecules which encode the genetic information to be transferred and contain all 
necessary regulatory elements for successful gene expression (e.g. promoters and 
polyadenylation signal). Such vector systems serve for the transfer of genetic 
material into cells and have different efficiencies in regard to expression level and 
duration (Thomas et al. 2003). 
A major distinction is made between transient and stable expression vector systems. 
Transient expression vectors temporarily transfer RNA- or DNA-based vectors into 
target cells, from which the desired proteins are expressed. The transfer of these 
vectors can be performed using physicochemical methods, such as electroporation 
(Neumann et al. 1982), calcium phosphate-mediated transfection (Graham and van 
der Eb 1973; Wigler et al. 1978; Jordan et al. 1996) or lipofection (Felgner et al. 
1987; Felgner et al. 1997). Disadvantages of physicochemical transfer methods are 
target cell type specific and include limited efficacy, high cytotoxicity or spontaneous, 
residual, unwanted integration events into the host cell chromatin (Hsiung et al. 1980; 
Robins et al. 1981; Chen and Okayama 1987; Murnane et al. 1990; Kjer and Fallon 
1991; Baum et al. 1994; O'Mahoney and Adams 1994; Nguyen et al. 2007). 
Transient protein expression can also be achieved through use of viral vector 
systems, which are naturally adapted to cellular pathways. Utilization of viral features, 
such as packaging and protection of genetic information in viral particles, which 
interact with cellular host factors (Brass et al. 2008), facilitates the entry into the 
cytoplasm and/or nucleus of a given cell. Examples are the adenoviral vector 
systems, which are used in many gene therapy trials (overview in 
http://www.wiley.co.uk/genetherapy/clinical), and the integrase-deficient lentiviral 
  Introduction    2   
     
vector systems (Yanez-Munoz et al. 2006; Philpott and Thrasher 2007). Both types of 
viral gene transfer establish nuclear episomal DNA structures, which are lost over 
time in dividing cell populations. Infrequently, spontaneous, residual integrations are 
observed, supported by the the cellular DNA recombination machinery. 
For applications in which a stable ectopic expression is desirable, it is preferred to 
use retroviral (based on gammaretroviral or lentiviral technology) vector systems, 
which incorporate their genetic information into the host genome. The ability of 
retroviruses to infect a variety of target cells coupled with the relatively well 
understood retroviral life cycle (see below), makes them promising candidates for 
human gene therapy. 
This work explores retroviral technology as a tool for the transient delivery of 
proteins, which presents with advantageous features including low cytotoxicitiy, 
specific cell targeting and prevention of residual integration events.  
 
1. Retroviruses and their replication 
a. Overview 
Retroviruses are plus-stranded, lipid-enveloped RNA viruses, approximately 100 nm 
in size, with either icosahedral (e.g. MoMuLV) or conical (e.g. HIV-1) capsids. The 
name “retrovirus” is based on the ability to retrograde the flow of information from 
RNA to DNA via a specific enzyme, the reverse transcriptase (RT). The family of the 
Retroviridae consists of the following 7 genera, whereof most were assigned to be 
exogenous retroviruses (Modrow et al. 2003).  
 
1) α-retrovirus (e.g. Rous sarcoma virus, RSV) 
2) β-retrovirus (e.g. Murine mammary tumour virus, MMTV) 
3) γ-retrovirus (e.g. Murine leukemia virus, MLV) 
4) δ-retrovirus (e.g. Human T-cell leukemia virus type 1, HTLV-1) 
5) ε-retrovirus (Fish retroviruses, e.g. Walleye dermal sarcoma virus, WDSV) 
6) Lentivirus    (e.g. Human immunodeficiency virus type 1, HIV-1) 
7) Spumavirus (e.g. Human foamy virus, HFV) 
 
In respect to the variety of proteins encoded by the retroviral genome, the retrovirus 
family can be further classified as simple or complex organized retroviruses. The 
genome of simple retroviruses (alpha-, beta- and gammaretroviruses) exclusively 
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encodes for the three viral proteins Gag (group-specific antigen, structural proteins), 
Pol (polymerase, enzymatic proteins) and Env (envelope protein). This set of genes 
is common to all retroviruses. In contrast, the genomes of complex retroviruses 
(delta-, lenti- and spumaviruses) harbor additional open reading-frames (ORF) for 
regulatory and accessory proteins. 
Retroviruses enter their target cells in a receptor-mediated manner, reverse 
transcribe their genomic RNA into double stranded DNA and integrate as a so called 
“provirus” into the host genome. All essential components for the generation of new 
virus progeny are then produced by taking advantage of the host transcriptional, 
translational and other cellular machineries. After assembly, the nascent virions are 
released at the cell surface by a so called “budding” process. The budding retroviral 
particles are initially immature and through subsequently processing of viral proteins 
within virions by the encoded viral protease, mature particles capable of infecting 
new target cells are produced. A more extensive description of the retroviral life cycle 
is provided below. Since the present work is based on the utilization of retroviral 
vectors derived from the gammaretroviral murine leukemia virus (MLV), the following 
paragraphs will mainly discuss the aspects of retroviral replication and retrovirus-host 
interactions in the light of simple structured gammaretroviruses. 
 
b. The gammaretroviral genome  
The genome of retroviruses (Fig. 1) consists of two copies of a linear, plus- and 
single-stranded RNA molecule of 7-12 kb. Similar to cellular messenger RNAs 
(mRNA), retroviral genomic RNA molecules are equipped with a 5´ Cap and a 3´ 
PolyA-tail (consisting of approximately 200 adenosine residues). Additionally, each 
genome carries a cellular tRNA molecule, which serves as the primer for the initiation 
of reverse transcription upon infection. 
The viral coding regions are flanked by regulatory sequences, which are essential for 
reverse transcription and the integration of the provirus into the host genome. The 5´ 
and 3´ end of the retroviral genome contains a redundant region (R-region) which 
entails the transcription start point and a polyadenylation signal. The 5´ R-region is 
followed by the U5 region (U=unique) which harbors one of the two integrase 
attachment sites (att). The adjacent primer binding site (PBS) binds via hydrogen-
bonds to the 3´ end of a tRNA-molecule, whose free 3´ hydroxyl group serves as 
initiation point for reverse transcription (Leis et al. 1993). In addition to the splice 
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donor site (SD), the sequence located between the PBS and the beginning of gag 
contains the highly structured packaging signal (Ψ) (D'Souza and Summers 2005), 
which is involved in dimerization as well as encapsidation of the retroviral genomes. 
This 5´ untranslated region (UTR), which comprises the sequences located between 
the Cap and gag, is termed the leader region. The following coding region consists of 
the three successive genes gag, pol and env, whereof expression of env is enabled 
through a splice acceptor (SA) in pol. The PPT (polypurine tract) is located 
downstream of the coding region and contains a series of at least 9 adenosine and 
guanosine residues important for the initiation of plus strand DNA synthesis during 
reverse transcription. Subsequent to the PPT and adjacent to the 3` R-region follows 
the U3 region. The U3 region is unique to the 3´ end of the retroviral genome and 
provides enhancer and promoter sequences for the regulation of retroviral gene 
expression as well as the second integrase attachment site. 
 
 
 
During infection, the retroviral RNA genome is reverse transcribed into double-
stranded DNA and integrated as a provirus into the host genome. In the process of 
reverse transcription, the 5´ R and U5 regions and the 3´ U3 region of the retroviral 
genome are each copied to the opposite termini. This results in a provirus flanked by 
long terminal repeats (LTR) consisting each of the U3, R and U5 sequences (Fig. 1). 
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c. The expression of gammaretroviral proteins 
The simply organized genome of gammaretroviruses encodes for the retroviral 
proteins Gag, Pol and Env. Whereas the structural Gag and enzymatic Pol proteins 
are expressed from the same unspliced (genomic) viral mRNA transcript, the Env 
glycoproteins originate from a spliced variant (Fig. 2).  
 
       
 
Since gag and pol form one large open reading frame that is separated by a stop 
codon, retroviruses had to evolve translational strategies allowing the expression of 
both proteins from a single unspliced mRNA transcript. Retroviruses solved this 
problem by the synthesis of a Gag/Pol polyprotein precursor, which is further 
proteolytically processed by the viral protease after budding (see below). In Moloney 
MLV (MoMLV) the reading frame of gag is terminated by an amber stop codon 
(UAG). This amber stop codon is occasionally misread by the tRNA for glutamine, 
thus allowing continued translation through pol (Yoshinaka et al. 1985). This process 
of “translational suppression of termination” is a well-known mechanism in bacteria, 
but is not known so far to occur in normal eukaryotic gene expression. In the case of 
MoMLV, the efficiency of translational suppression is about 4% to 10% and involves 
a purine-rich sequence 3´ of the amber stop codon, as well as an RNA pseudoknot 
structure further downstream. It has been suggested that the pseudoknot causes the 
ribosome to pause and, together with the eight-nucleotide, purine-rich segment of the 
suppression signal, allows the suppressor tRNA (glutamine) to compete with 
translational termination/release factors at the suppression site. Interestingly, the Pol 
protein of MLV regulates its own synthesis by modulating translational read-through. 
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The RT protein of the Gag/Pol precursor binds and inhibits the mammalian 
translational release factor eRF1, thereby increasing the misreading frequency of the 
stop codon by the glutamine tRNA (Orlova et al. 2003). The resulting increased level 
of Gag/Pol production is suggested to be required for production of infectious 
particles. 
After synthesis, the Gag and Gag/Pol precursor molecules are myristoylated at their 
N-terminus, packaged into viral particles and following budding subsequently 
processed into their single components by the viral protease. Whereas the Gag 
precursor of MLV is cleaved into the components matrix (MA, p15), p12, capsid (CA, 
p30), and nucleocapsid (NC, p10), Pol is processed into protease (PR, p14), reverse 
transcriptase (RT, p80) and integrase (p46) (see also Fig. 1).  
The glycoprotein (Env) of retroviruses is embedded in the lipid envelope of the virion 
and consists of two subunits, which are initially expressed as a precursor molecule 
from the spliced subgenomic retroviral env RNA. The N-terminal glycoprotein subunit 
is designated the surface (SU) subunit and is responsible for binding to the ecotropic 
receptor on target cells. The carboxy-terminal subunit, which anchors the virus 
protein in the viral envelope, is termed the transmembrane (TM) subunit. Unlike the 
translation of Gag and Gag/Pol precursors, which takes place at free polyribosomes, 
the retroviral Env precursor (gp85env) of MLV is synthesized, like other cell surface 
proteins, at polyribosomes associated with the rough endoplasmic reticulum (rER). 
Following translation into the lumen of the rER, the nascent Env polypeptides 
trimerize and undergo a glycolysation process (addition of N-linked oligosaccharides, 
mostly mannose sugars). Subsequently, the nascent Env glycoproteins are 
transported to the Golgi apparatus, where the N-linked oligosaccharides are further 
modified (trimming of the high mannose core, addition of other carbohydrates to the 
branches, addition of terminal sialic acid residues) and a cellular protease of the furin 
family cleaves the Env precursor molecule into the hydrophilic SU (gp70env) and the 
hydrophobic TM (p15env) moieties (Pinter et al. 1978; Henderson et al. 1984; Kamps 
et al. 1991). During virus budding, the viral protease cleaves TM to generate p12env 
and p2env molecules (Van Zaane et al. 1976), thereby activating the Env protein for 
fusion (Rein et al. 1994). 
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d. The gammaretroviral particle 
Nascent retroviruses bud from the host membrane in a rather immature state. These 
immature particles are enveloped and consist each of an internal viral core that is 
formed by Gag and Gag/Pol precursor proteins embedding two copies of the plus-
stranded retroviral RNA genome. Subsequently, processing of the Gag and Gag/Pol 
proteins into their subunit components by the viral protease (see above) during 
and/or shortly after the budding process leads to structural reorganization of the inner 
protein core, thereby generating mature and infectious virions. A schematical 
illustration of a mature gammaretroviral particle is given in figure 3. The mature 
gammaretroviral particle consists of an internal core, whose shell is formed by the 
viral CA proteins giving the core its icosahedral structure. The inner part of the core 
houses the retroviral genome complexed with NC proteins, the viral enzymes PR, RT 
and IN as well as cellular factors like the primer tRNA essential for replication. The 
core is covered with a layer of the p12 protein, whose exact function remains to be 
elucidated. The MA protein is found adjacent to p12 and in closest association with 
the viral envelope. The modification of the amino termini of the MA proteins by the 
addition of fatty, myristic acid groups during the translation of Gag allows MA direct 
interactions with the cell membrane derived viral lipid envelope. The viral core, p12 
and MA proteins are surrounded by the envelope, in which the processed Env 
proteins are deposited (Levy 1993). 
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e. The retroviral life cycle 
The infectious and mature retroviral particle (Fig. 3) contains two plus-stranded RNA 
genomes embedded within the viral protein core. The latter is surrounded by a cell 
membrane-derived envelope bearing the glycoproteins (encoded by Env) necessary 
for the initiation of infection. The retroviral life cycle (Fig. 4) can be divided into early 
and late phases of replication, as described below. 
 
 
Early phases of replication  
In the first step of infection, the virion envelope glycoprotein binds to specific and 
reciprocal cell surface receptor/s (Fig. 4). Subsequently, the viral envelope 
membrane fuses with the host membrane, either at the cell surface or after 
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internalization into endosomes, leading to the release of the internal virion core into 
the cytoplasm. Soon after viral penetration into the cell cytoplasm and a poorly 
understood uncoating step, the reverse transcription of the retroviral genome into 
double-stranded proviral DNA is initiated. 
As already mentioned, the retroviral enzyme responsible for retrograding the viral 
RNA genome into DNA is the reverse transcriptase (RT) (Baltimore 1992). RT 
combines two enzymatic properties, DNA polymerase activity and ribonuclease H 
(RNase H) activity, within one molecule. It uses both RNA and DNA as templates for 
DNA synthesis (Hurwitz and Leis 1972; Leis and Hurwitz 1972) and cleaves RNA 
within an RNA/DNA hybrid (RNase H activity) (Molling et al. 1971; Hansen et al. 
1987; Starnes and Cheng 1989). Because RTs lack proofreading activity and have 
been shown to be error-prone in vitro, they are presumed to contribute to the high 
mutation rate seen in retroviruses (Preston et al. 1988; Goodenow et al. 1989).  
As shown in figure 5, MLV reverse transcription is initiated by RT-catalyzed synthesis 
of the minus strand DNA using the free 3´ OH residue of the host derived tRNAPro 
primer (Peters et al. 1977). Since tRNAPro complementarily binds the MLV PBS, 
which is located at the 5´ end of the retroviral RNA genome, the earliest product 
during minus strand DNA synthesis is a copy of the short region consisting of R and 
U5 lying between the PBS and the 5´ end of the RNA genome (Coffin and Haseltine 
1977). This first reverse transcription intermediate is called minus strand strong stop 
DNA. Once minus strand strong stop DNA is generated, the newly made strand is 
translocated to the 3´ end of the retroviral RNA genome in order to complete 
synthesis of full-length minus strand DNA (Telesnitsky and Goff 1993). This process 
is described as minus strand transfer and is dependent on RT polymerase and 
RNase H activity as well as template homology. During minus strand transfer, the R 
region at the 3´ end of the strong stop DNA anneals to the 3´ R region of the genomic 
RNA, thereby allowing continued full-length minus strand synthesis. Concomitant 
with synthesis of the full-length minus DNA strand, the RNase H cleaves the newly 
copied RNA genome into short oligonucleotide fragments from either the 5´ or 3´ end 
(Mizrahi 1989). While many of these oligonucleotides can dissociate from the 
nascent minus DNA strand, the PPT sequence located upstream of the 3´ U3 region 
is resistant to RNase H cleavage. Therefore, the PPT sequence remains associated 
with the nascent minus DNA strand and serves as primer for plus strand DNA 
synthesis (Charneau et al. 1992). Plus strand synthesis initiates at the 3´ end of the 
PPT sequence and continues to the 5´ end of the minus strand DNA, thereby using 
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the first 18 nucleotides of the tRNA primer as a template for the generation of the 
PBS (Gilboa et al. 1979). Subsequently, the tRNA primer is removed by RNase H 
activity and a second strand transfer occurs, whereby the newly generated plus 
strand strong stop DNA is transferred to the 3´ PBS sequence of the minus strand 
DNA (Ben-Artzi et al. 1996). Finally, minus and plus strand DNA synthesis resumes, 
with each strand using the other as a template until the double stranded DNA 
containing LTR termini is fully synthesized. Interestingly, it has been shown that 
minus strand strong stop DNA is transferred at similar frequencies to the 3´ end of 
the same or the other co-packaged retroviral RNA genome, whereas plus strand 
transfer seems to predominantly occur intramolecularly (van Wamel and Berkhout 
1998; Yu et al. 1998). 
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The viral complex in which reverse transcription occurs is called the reverse 
transcription complex or RTC. So far, little is known about the structure, the 
composition and the properties of the RTC, particularly during the early steps after 
virus internalization. In 1999, Goff and colleagues demonstrated that the RTC of 
MoMLV contains integrase (IN) and capsid (CA) proteins in addition to the viral RNA 
genomes and the reverse transcriptase (RT) proteins (Fassati and Goff 1999). The 
process of reverse transcription, which is generally completed within 8 to 12 h, leads 
to the formation of the cytoplasmic preintegration complex (PIC). The cytoplasmic 
PIC of MLV has a relatively large size, sedimenting at 160S. The PIC contains the 
synthesized full-length, linear viral DNA, retains components of the virion core 
(including MA, CA, NC, RT and IN), and is, if isolated, competent to integrate the 
DNA in vitro (Bowerman et al. 1989). Recently, at least two host proteins have been 
found to be important for proper PIC structure and function. One is BAF-1 (barrier to 
auto-integration factor-1), a small DNA-binding protein identified as a component of 
the MLV and HIV-1 PIC (Chen and Engelman 1998; Suzuki and Craigie 2002; Lin 
and Engelman 2003; Mansharamani et al. 2003). BAF-1 is suggested to bridge the 
viral DNA in a discrete, higher-order nucleoprotein complex and thereby avoids a 
suicidal autointegration of the viral termini into internal sites on the viral DNA (Umland 
et al. 2000; Zheng et al. 2000). The second host component of the MLV PIC, which 
has been identified, is the lamina-associated polypeptide 2α (LAP2α), a component 
of the nuclear envelope which is required for infection by MLV (and by HIV-1 entering 
the cell using the HIV envelope protein) (Jacque and Stevenson 2006). LAP2α was 
shown to bind BAF-1 (Shumaker et al. 2001) and promote productive PIC integration 
(Suzuki et al. 2004). 
How does the retroviral PIC reach the nucleus? The mechanism is poorly 
understood, but it seems rather unlikely that the relatively large PIC passes through 
the viscous cytoplasm which is filled with cytoskeleton networks, organelles and 
cellular vesicles by simple diffusion (Goff 2007). For HIV-1, it was demonstrated that 
the PIC traffics to the nucleus by latching onto dynein motor proteins and moving 
along the microtubules (McDonald et al. 2002; Goff 2007). This might also be true for 
MLV, although treatment of cells with nocodazole, which depolymerizes micro-
tubules, affects MLV infection in some but not all cell-types (Kizhatil and Albritton 
1997). 
When the PIC has reached the nucleus, it must cross the nuclear membrane to 
integrate its reverse transcribed genome into the host genome (Suzuki and Craigie 
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2007). In contrast to HIV-1, which is able to infect dividing as well as nondividing 
cells, MLV depends upon mitosis to gain access to the host´s chromosomal DNA. It 
was shown that MLV derived PICs solve the nuclear entry problem by waiting for the 
nuclear envelope to disperse during mitosis (Harel et al. 1981; Miller et al. 1990; Roe 
et al. 1993; Lewis and Emerman 1994; Hatziioannou and Goff 2001). When the cell 
cycle is arrested at the G1-S transition by serum starvation or chemical treatment 
(e.g. aphidicolin), MoMLV PICs containing full-length viral DNA are present in the 
cytoplasm, but integration is blocked (Roe et al. 1993). Interestingly, when allowing 
the cell cycle to progress to metaphase, during which the nuclear envelope breaks 
down, the replication block is released and integration occurs (Roe et al. 1993).  
After gaining access to the host´s chromatin, the reverse transcribed linear DNA is 
integrated into the genome via the viral integrase. During the step-wise integration 
reaction, the viral integrase binds to the integrase attachment sites, which are located 
at the ends of the 5’ and 3’ LTRs after reverse transcription. Initially, the integrase 
removes two bases from the 3’ strand (3’ end processing), adjacent to a highly 
conserved CA dinucleotide, leaving a highly nucleophilic free 3’ OH-group. When 
brought together with the target cell genome, a nucleophilic attack by the 3’ OH-
group on a phosphate residue of the exposed 3’ end of the cell genome is initiated. 
This is follwed by a strand transfer and joining reaction. The remaining gap is then 
filled by the cellular DNA repair machinery (Engelman et al. 1991; Vink et al. 1991; 
Hindmarsh and Leis 1999; Lewinski and Bushman 2005). 
The position at which a retroviral genome integrates into the host cell genome is not 
random. Different integration preferences have been identified for individual 
retroviruses. Whereas MLV has a tendency to integrate into promoter-dense regions 
(near the transcriptional start site), HIV-1 prefers gene-dense regions and favorably 
integrates into transcription units (Schroder et al. 2002; Wu et al. 2003; Hematti et al. 
2004). Interestingly, the integrase itself has been been identified to be a major 
determinant of integration site selection (Lewinski et al. 2006; Derse et al. 2007). Of 
note, a cellular tethering factor (lens epithelium derived growth factor) has been 
identified for HIV-1, but not (yet) for MLV.  
 
Late phases of replication 
After integration, the retroviral gene expression follows cellular rules. By taking 
advantage of the cellular Polymerase II, the retroviral genes are transcribed, spliced 
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if necessary (see env transcript), polyadenylated and exported into the cytoplasm 
either for translation of the retroviral precursor proteins or, in case of the unspliced 
genomic RNA transcript, also for encapsidation into newly forming virions. As already 
mentioned, Env proteins are synthesized at the rER and subsequently transported to 
the plasma membrane via the secretory pathway. In contrast, the retroviral Gag and 
Gag/Pol precursors are cytosolic proteins that are synthesized at free polyribosomes 
and are subsequently myristoylated at their N-termini. However, production of 
infectious retroviral particles requires the co-localization and assembly of retroviral 
cytosolic and transmembrane proteins as well as the retroviral RNA genomes at the 
membrane budding site. Initially, the budding site has been postulated to be localized 
at the plasma membrane. However, recent reports suggest that budding also occurs 
in multivesicular bodies (MVBs) (Nguyen and Hildreth 2000; Pelchen-Matthews et al. 
2003; Sherer et al. 2003; Houzet et al. 2006). MVB are late endosomal com-
partments which accumulate internal vesicles produced from intracisternal 
invagination of the endosomal membrane. These internal vesicles are released either 
into lysosomes to allow associated protein and lipid degradation or into the 
extracellular space as exosomes for intercellular communication (Thery et al. 2002). 
Three major domains within the Gag precursor are important for assembly and 
release of virus progeny. These domains are referred to as membrane targeting (M), 
interacting (I) and late (L) domains. The M-domain is located at the N-terminus of the 
matrix protein. Myristoylation of the N-terminal glycine of the matrix protein mediates 
the association of Gag and Gag/Pol precursors with cellular membranes (Hill et al. 
1996; Suomalainen et al. 1996; Ono and Freed 1999). In addition, matrix contains a 
stretch of basic residues that are also believed to stabilize its association with the 
plasma membrane (Freed 1998; Garoff et al. 1998). The I-domain promotes Gag-
Gag multimerization that drives the assembly process and is located within the 
nucleocapsid protein (Sandefur et al. 2000; Derdowski et al. 2004). When the virus is 
successfully assembled, the viral membrane must separate (bud) from the cellular 
membrane. The budding and pinching off of retroviral particles is mediated by the L-
domain, which is a tetrapeptide PPPY sequence in the p12 protein or PTAP 
sequence in p6 for MLV and HIV, respectively (Huang et al. 1995; Yuan et al. 1999). 
Interestingly, late domain sequences were found to direct the interaction between the 
Gag protein and some cellular host factors involved in the protein sorting process 
and vesicle formation during the MVB biogenesis (Garrus et al. 2001; VerPlank et al. 
2001; Wang et al. 2003; Demirov and Freed 2004). It seems that retroviruses have 
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evolved mechanisms to hijack complexes of the MVB machinery (e. g. endosomal 
sorting complexes required for transport, ESCRTs), thereby promoting their release 
from the cell.  
The encapsidation of retroviral RNA genomes within nascent virions is a further 
prerequisite for retroviral infectivity. Once delivered into the cytoplasm, unspliced, 
genomic viral mRNA serves as a protein synthesis template and as a viral genome 
when packaged. For HIV-1, it was demonstrated that the RNA genome, which is 
packaged into a retroviral particle, can be the same as that used for the translation of 
the gag/pol gene. (Butsch and Boris-Lawrie 2002; Poon et al. 2002; Anderson and 
Lever 2006). In contrast, the genome of MLV appears to be mainly segregated into 
two distinct populations that function independently as genomic RNA for packaging 
into progeny virions or as an mRNA template for protein synthesis (Levin et al. 1974) 
(Levin and Rosenak 1976; Dorman and Lever 2000). 
How is encapsidation of the two retroviral RNA genomes regulated? Although the 
exact mechanism is still under investigation, it has been shown that packaging of 
retroviral RNA genomes in nascent virions is mediated by specific interactions 
between the retroviral NC domain of Gag and the highly structured packaging signal 
Ψ of the viral genome. The NC domains of all retroviruses, except the spuma-
retroviruses, contain one or two conserved Cys-X2-Cys-X4-His-X4-Cys (X = variable 
amino acid) zinc finger motifs that bind specifically to sequences within Ψ 
(Henderson et al. 1981; D'Souza and Summers 2004). After dimerization of two RNA 
genomes, possibly promoted by the nucleic acid chaperone activity of NC (Darlix et 
al. 1995), high-affinity binding sites within Ψ are exposed to mediate packaging of 
these two genomic RNA molecules into the viral particle. Since the spliced env 
transcripts and cellular RNAs lack Ψ sequences, preferentially the full-length RNA 
genomes are incorporated into new viral progeny. Of note, cellular RNAs (e.g. 
mRNAs and tRNAs) have been also detected in purified retroviruses, an event which 
is assumed to occur randomly and at low rates (Muriaux et al. 2001; Rulli et al. 
2007). 
Less is known about the site where Gag captures the RNA genomes. However, it has 
been shown for HIV-1 that Gag interacts with the RNA genomes at or adjacent to the 
centriole, near the nuclear membrane (Poole et al. 2005). In addition, it was shown 
that MLV RNA genomes traffic in association with Gag along recycling endosomal 
vesicles (Basyuk et al. 2003).  
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Once assembly is completed, the viral particles are released and extracellular 
conversion creates a fully infectious particle (as described above).  
 
2. The retroviral vector system 
 
Retroviruses are well adapted to their hosts and infect a variety of cells. They enter 
the cytoplasm in a receptor mediated manner, and stably integrate their viral genes 
into the host genome after reverse transcription. Due to these abilities, retroviruses 
represent a useful tool for the delivery of genetic information into target cells. By 
inserting the gene of interest (transgene) within the retroviral genome and taking 
advantage of all retroviral proteins necessary for successful infection, retroviral 
particles serve as well evolved and specialized “gene ferries” that permit the transfer 
of genetic information into the nucleus of a target cell. To avoid the generation of 
replication competent retrovirus (RCR), it is necessary to separate genes encoding 
for structural and enzymatic proteins (Gag/Pol) as well as the gene encoding 
envelope proteins (Env) from the retroviral genome (i.e. the so-called split packaging 
design) (Fig. 6). The result is a so-called “retroviral vector”, which still contains the 
packaging signal (Ψ), the primer binding site (PBS) and the long terminal repeats 
(LTR), but harbors the transgene instead of genes encoding for structural and 
enzymatic retroviral proteins. The viral structural proteins (Gag) and replication 
enzymes (Pol) as well as the glycoproteins (Env) are encoded on separate helper 
expression plasmids, which lack all other retroviral components including the 
retroviral packaging signal. To lower the probability of recombination events, which 
could recreate a wild-type retrovirus, the genetic information for gag/pol and env are 
usually located on separate expression plasmids. For the production of 
gammaretroviral vector particles, both Gag/Pol and Env proteins as well as the 
retroviral vector construct are either transiently or stably co-expressed in so-called 
“packaging cell lines” (e.g. human embryonic kidney derived 293T cells) (Fig. 6). 
Since gag/pol and env expression constructs lack the packaging signal, viral 
structural proteins only recognize the Ψ-containing retroviral vector construct leading 
to a preferential packaging of retroviral vector genomes into infectious particles. After 
entry of the particle into the target cell (transduction), only the nucleic acid of the 
retroviral vector construct is reverse transcribed and stably integrated into the host 
genome. Since gag/pol and env are only transferred in the form of proteins (and not 
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as nucleic acid) the generation of replication competent retroviral vector progeny is 
prevented.  
 
 
a. The gammaretroviral vector used in this study 
Retroviral vectors, derived from gammaretroviruses (Miller and Rosman 1989) or 
lentiviruses (Naldini et al. 1996), are most frequently used for gene therapy 
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applications. The gammaretroviral vector constructs used in this study (Fig. 7) are 
derived from Moloney MLV and were optimized stepwise for high transgene 
expression levels in early hematopoietic cells (Baum et al. 1995; Hildinger et al. 
1999; Schambach et al. 2000). Substitution of the enhancer/promoter region (3´ U3) 
of MoMLV within the retroviral genome with enhancer/promoter sequences from the 
polycythemic strain of mouse spleen focus-forming virus (SFFV) leads to higher 
expression levels in both multipotent and lineage-committed hematopoietic cells 
(Baum et al. 1995). The PBS sequence of MoMLV (complementary to the 3´ end of 
the tRNAPro) negatively controls viral gene expression by transcriptional silencing in 
embryonic carcinoma (EC) and embryonic stem cells (Kempler et al. 1993;Teich et 
al. 1977; Barklis et al. 1986). This repression has been overcome in the 
gammaretroviral vector used here by introducing the PBS sequence (complementary 
to the 3´end of the tRNAGlu) of murine embryonic stem cell virus (MESV) (Grez et al. 
1990). Recently, the factor which is responsible for the repression has been identified 
to be the tripartite motif 28 (TRIM28) (Wolf and Goff 2007), a nuclear protein that is 
known as a transcriptional corepressor (Le Douarin et al. 1996; Schultz et al. 2001; 
Schultz et al. 2002). The removal of all potential and aberrant ATG start codons 
within the 5´ UTR leader, the introduction of a minimal splice acceptor site, thereby 
generating a functional intron including the packaging signal, or the addition of the 
woodchuck posttranscriptional regulatory element (wPRE, derived from woodchuck 
hepatitis virus) further improved transgene expression from gammaretroviral vector 
constructs (Hildinger et al. 1999; Zufferey et al. 1999; Schambach et al. 2000). 
 
 
 
b. Non-integrating retroviral vectors 
The infection of target cells with functional retroviral vector particles usually results in 
stable ectopic transgene expression. However, integration of foreign DNA into the 
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genome can influence the expression of neighboring alleles (Hayward et al. 1981; 
Kung et al. 1991; Barker et al. 1992; Fan 1994). Replication-deficient vectors can 
lead to “insertional mutagenesis” causing dysregulation of neighboring genes, e.g. 
proto-oncogenes with subsequent induction of leukemia (Li et al. 2002; Hacein-Bey-
Abina et al. 2003b). Non-integrating vector tools might be of interest for some gene 
therapeutic or other applications in biotechnology or basic research in order to 
express the selected transgene in a non-permanent manner. Since conventional 
transient expression methods (e.g. transfection of nucleic acids) are in general 
limited in terms of gene transfer and can lead to toxicity (particularly in primary cells), 
the development of new and improved transient expression methods is of great 
interest.  
An alternative and novel transient expression method for the ectopic expression of 
proteins is the use of integrase-deficient lentiviral vector particles. The disruption of 
normal retroviral integrase function by introducing specific point mutations within the 
integrase sequence allows the molecular separation of cellular and nuclear entry 
from the intrinsic integration process. As shown in figure 8, the lentiviral integrase 
protein consists of an N-terminal zinc finger domain followed by a catalytic core 
domain and a C-terminal DNA-binding domain (Engelman et al. 1993). The catalytic 
domain comprises a core DDE amino acid sequence motif that is absolutely required 
for successful integration and is common with all retroviral integrase proteins as well 
as many cellular and bacterial transposases (Engelman and Craigie 1992; Kulkosky 
et al. 1992) (Johnson et al. 1986; Baker and Luo 1994; Radstrom et al. 1994). The 
DDE motif of the HIV integrase is located at positions D64, D116 and E152. Point 
mutations which result in amino acid changes at these positions specifically inhibit 
the integration of the lentiviral DNA into the host genome and result in an episomal 
intermediate (linear DNA, 1LTR and 2LTR circles) (Leavitt et al. 1993; Ansari-Lari et 
al. 1995; Wiskerchen and Muesing 1995; Leavitt et al. 1996). However, despite of the 
destruction of the catalytic core domain of the retroviral integrase (within the DDE 
motif), residual integration events are still observed. The quantification of residual 
integration events revealed that integrases with D116I mutations integrated 3 log 
units less efficiently compared to wild-type integrases; and integrases with D64V or 
E152G mutations are 4 log units less efficient than wild-type integration events 
(Leavitt et al. 1996). Combination of the D64V with att site mutations did not further 
decrease residual integration events and subsequent integration site analysis 
suggested that residual integration events of the D64V mutant was not mediated by 
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integrase but by background integration events (Nightingale et al. 2006). Thus, the 
development of new techniques for the transient expression of proteins for cell 
manipulation would be of great interest and is addressed in this study.  
 
     
 
3. Retroviral restriction factors 
Retroviruses are obligatory intracellular parasites that have coevolved with their 
hosts over millions of years. They cause infections which are responsible for 
significant diseases in mammals, including a variety of pathologies such as immune 
deficiency, malignancies, and neurological and immunological symptoms. Therefore, 
it is not surprising that mammals evolved antiviral defense mechanisms to protect 
themselves against these pathogens. Besides type I (α and β) interferons, which are 
historically considered to be the first line of defense against viral infection (Isaacs and 
Burke 1958), mammals have evolved additional proteins to counteract viruses. One 
well-known example of a retroviral restriction factor is the family of apolipoprotein B 
mRNA-editing enzyme catalytic proteins (APOBEC), which are cytidine deaminases 
capable of removing the amino group from cytosine to form uracil. Human 
APOBEC3G and APOBEC3F were shown to have potent inhibitory activity against 
HIV-1 (Sheehy et al. 2002; Wiegand et al. 2004; Zheng et al. 2004) by hypermutating 
the incoming retroviral genome during reverse transcription. However, recent data 
indicate that APOBEC proteins act against the virus by blocking accumulation of 
complete reverse transcription products rather than through their enzymatic cytidine 
deaminase activity (Bishop et al. 2006; Holmes et al. 2007a; Holmes et al. 2007b). 
The restriction factor is packaged into virions in producer cells, but does not display 
its negative influence on viral replication until the viral RNA is reverse transcribed in 
the target cell. Interestingly, HIV-1 has coevolved a strategy to prevent the 
deleterious actions of APOBEC3G. The HIV-1 Vif protein apparently binds to 
APOBEC3G in the producer cell and prevents its packaging into the virus by 
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targeting it to the proteasomal degradation pathway (Mariani et al. 2003; Yu et al. 
2003).  
Several other viral restriction factors have been identified and cloned so far. Among 
these is the zinc finger antiviral protein (ZAP). ZAP posttranscriptionally inhibits the 
replication of MoMLV and several alphaviruses by preventing the accumulation of de 
novo synthesized viral RNA in the cytoplasm (Gao et al. 2002) (Bick et al. 2003). It 
has been shown that the N-terminal located CCCH-type zinc finger motifs of ZAP 
directly bind defined sequences within the viral genome and presumably target it to 
an exoribonuclease complex for degradation (Guo et al. 2004).  
Other retroviral restriction factors, such as the Friend virus susceptibility factor 1 
(Fv1) and the cytoplasmic body component TRIM5α (a member of the tripartite motif 
family of proteins) target the incoming retroviral capsid instead of the retroviral 
nucleic acid. Since part of this study is based on the interaction of gammaretroviral 
particles with Fv1 or TRIM5α, these two restriction factors are explained below in 
more detail.  
 
a. The restriction factor Fv1  
The first gene described to display retroviral restriction properties in mammals is the 
friend virus susceptibility factor 1 (Fv1). Fv1 was found to confer resistance of inbred 
strains of mice to leukemia caused by MLV (Lilly 1967). Two main alleles of Fv1 have 
been described, Fv1n from NIH mice and Fv1b from BALB/c mice. The specific 
restriction ability also enables the division of MLVs into two subgroups depending on 
their tropism for these two mouse strains (Steeves and Lilly 1977). Thus, N-tropic 
MLV (N-MLV) strains are able to cause leukemia in NIH mice (Fv1n/n) but do not 
infect BALB/c mice (Fv1b/b). Conversely, B-tropic MLV strains (B-MLV) infect BALB/c 
(Fv1b/b) but not NIH mice (Fv1n/n). Since the Fv1 gene is inherited co-dominantly, 
crossing NIH mice with BALB/c mice generated a heterozygous phenotype, which 
restricted both N-MLV and B-MLV (Rowe and Hartley 1972). NB-tropic MLVs, such 
as the common lab strain MoMLV (Moloney 1960), are able to replicate well in both 
BALB/c and NIH cells and do not show any apparent sensitivity to Fv1. However, 
recent studies involving over-expression of Fv1b indicate that its gene product can 
interact to a certain degree with both N-tropic and NB-tropic virus (Bock et al. 2000). 
The main viral determinant conferring susceptibility to either Fv1n or Fv1b is the amino 
acid residue at position 110 within the retroviral capsid. Whereas N-tropic MLV 
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harbors an arginine residue at that position, which determines the sensitivity to Fv1b, 
the glutamate residue within the capsid of B-MLV is responsible for the susceptibility 
to restriction by Fv1n (Kozak and Chakraborti 1996). Interestingly, substitution of 
arginine 110 of N-MLV with glutamate creates a B-tropic-like particle which is 
sensitive to Fv1n. The opposite (i.e. conversion of glutamate 110 of B-MLV into 
arginine) renders B-MLV sensitive to Fv1b. On the other hand, conversion of B- or N-
tropic MLV into NB-tropic particles is more complex and requires a number of 
additional amino acid changes (Kozak 1985; Stevens et al. 2004; Lassaux et al. 
2005).  
Fv1 encodes a Gag-like protein, which exhibits sequence similarities to the gag gene 
(approximately 60%) of endogenous retroviral elements (ERV-L, endogenous 
retrovirus with leucine t-RNA primer) in mice and humans (Best et al. 1996; Benit et 
al. 1997). Hypothesizing a gammaretrovirus-like Gag processing of ancient ERV-L, 
the homology of Fv1 to Gag covers a region extending from matrix through capsid 
and into the first part of the nucleocapsid. The most likely reason for the survival of 
the Fv1 ORF and the loss of the surrounding retroviral sequences might be a 
selective pressure provided by pathogenic MLV infection. 
It has been shown that Fv1 blocks MLV in a saturable manner and that capsid 
processing is essential for recognition by Fv1 (Dodding et al. 2005). It is suggested 
that early after cellular entry, Fv1 binds the capsid of the incoming particle, still 
allowing reverse transcription of the retroviral genome, but blocking the formation of 
circular viral DNA. Since the latter is thought to be indicative for nuclear entry, the 
observation of reduced circular viral DNA levels in a restrictive cell implies that Fv1 
blocks infectivity before nuclear entry (Jolicoeur and Rassart 1980; Yang et al. 1980). 
However, the exact mechanism by which Fv1 restricts MLV is currently unknown and 
still needs to be elucidated. 
 
b. The tripartite motif TRIM5α  
Members of the TRIM protein family are involved in various cellular processes, 
including cell proliferation, differentiation, development, oncogenesis and apoptosis. 
Some TRIM family members possess antiviral properties, which target retroviruses in 
particular. One of the TRIM family members displaying antiviral features is the 
cytoplasmic protein TRIM5α, the largest isoform of at least three splice variants of the 
TRIM5 gene (α, γ and δ). So far, a variety of TRIM5α cDNAs from a large number of 
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primates and bovines have been cloned and tested for antiviral activity against 
retroviruses (Song et al. 2005; Ohkura et al. 2006; Si et al. 2006; Ylinen et al. 2006). 
Interestingly, the virus specificity of TRIM5α proteins is species-dependent. The 
TRIM5α protein expressed in rhesus macaque cells (rhTRIM5α) potently restricts 
HIV-1, whereas the human variant of TRIM5α (huTRIM5α) only modestly inhibits 
HIV-1 but clearly affects the infection of N-tropic (N-MLV), but not B-tropic murine 
leukemia virus (B-MLV).  
Although the exact mechanism of TRIM5α restriction is still under investigation, it was 
demonstrated that TRIM5α, like Fv1, interacts with the capsid of the retroviral particle 
at an early postentry step (Himathongkham and Luciw 1996; Towers et al. 2000; 
Besnier et al. 2003; Passerini et al. 2006; Towers 2007). However, in contrast to Fv1, 
TRIM5α usually does not allow the reverse transcription of the retroviral genome 
(Shibata et al. 1995; Himathongkham and Luciw 1996; Towers et al. 2000; Besnier et 
al. 2002; Cowan et al. 2002; Munk et al. 2002). Interestingly, squirrel monkey 
TRIM5α, which restricts SIVmac, does not block SIVmac DNA synthesis (Ylinen et al. 
2005), rather resembling the Fv1-like restriction mechanism.
 
 
Similar to Fv1, the susceptibility of gammaretroviral particles to huTRIM5α is mainly 
controlled by the amino acid residue at position 110 within the retroviral capsid. The 
arginine 110 of N-MLV confers sensitivity to huTRIM5α, whereas the corresponding 
glutamic acid residue within the B-MLV capsid renders the particle insensitive to 
restriction (Towers et al. 2000; Perron et al. 2004). Replacement of glutamic acid 110 
of the B-MLV capsid with arginine generates a virus that is susceptible to huTRIM5α 
restriction. Conversely, replacing the arginine residue of the N-MLV capsid with the 
corresponding glutamic acid residue from B-MLV generates a virus that can only 
partially overcome huTRIM5α restriction (Perron et al. 2007), arguing for the 
involvement of additional amino acid residues in this specific setting.  
The fact that restriction of retroviral particles by TRIM5α usually inhibits the 
accumulation of reverse transcription products may implicate degradation of retroviral 
nucleic acids as part of the TRIM5α restriction process. However, to date there is no 
evidence that TRIM5α directly or indirectly (by an unknown factor X) targets the 
retroviral RNA for degradation, thereby preventing reverse transcription (Chatterji et 
al. 2006).  
A common feature of all TRIM proteins, including TRIM5α, is the RBCC motif, which 
comprises a RING (“really interesting new gene”) domain, a Bbox-2 and a predicted 
coiled-coil region. In addition to the RBCC motif, each TRIM contains a specific 
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carboxyl-terminal (C-terminal) domain. In the case of TRIM5α, the specific C-terminal 
is the B30.2 or PRYSPRY domain (Fig. 9), a motif also found in members of the 
immunoglobulin superfamily. 
 
    
 
The C-terminal PRYSPRY domain forms one compact 13-stranded β-sandwich, 
containing a hydrophobic core and a putative ligand-binding pocket. Although all 
attempts of conventional co-immunoprecipitations have failed so far, the PRYSPRY 
domain of TRIM5α has been proven to be the specificity determinant for retroviral 
restriction (Stremlau et al. 2004; Sawyer et al. 2005; Sebastian and Luban 2005; Yap 
et al. 2005). It is suggested that PRYSPRY interacts directly with the incoming 
retroviral capsid and perturbs the continuation of the infectious cycle. Since virus-like 
particles (not containing nucleic acid) saturate TRIM5α restriction activity, but the 
expression of capsid monomers in a restrictive cell does not (Dodding et al. 2005), 
TRIM5α seems to recognize rather a higher order structure of capsid multimers 
(Mortuza et al. 2004). Deletion of the PRYSPRY domain completely abrogates the 
efficacy of TRIM5α to restrict HIV-1 or N-MLV (Stremlau et al. 2004; Perez-Caballero 
et al. 2005a). Mutational analyses of TRIM5α showed that the amino acid 
composition between approximately residues 320 and 345 within the PRYSPRY 
domain confers the specificity of retroviral restriction among hosts (Nakayama et al. 
2005; Perez-Caballero et al. 2005a; Sawyer et al. 2005; Stremlau et al. 2005; Yap et 
al. 2005). Interestingly, altering the arginine at position 332 of huTRIM5α to the 
proline residue found in the PRYSPRY domain of rhTRIM5α results in a protein that 
can potently restrict HIV-1 and, surprisingly, SIVmac infection (Stremlau et al. 2005; 
Yap et al. 2005). A further study revealed that even the removal of this positively 
charged arginine residue 332 within the PRYSPRY domain of huTRIM5α is sufficient 
to allow huTRIM5α to bind HIV-1 capsids and to restrict infection (Li et al. 2006).  
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The N-terminal RING domain is a specialized zinc finger, which binds two zinc atoms 
via two cysteine residues, forming a “cross-brace” motif. The role of the RING domain 
during TRIM5α-mediated restriction is currently unknown. It has been shown that 
RING finger mutants (mutations of the Zn-coordinating cysteine residues) of TRIM5α 
retain partial restriction activity (Perron et al. 2004; Stremlau et al. 2004; Javanbakht 
et al. 2005; Perez-Caballero et al. 2005b), indicating that the RING domain is not 
absolutely required but also not completely dispensable for function during retroviral 
restriction. Since an ubiquitin auto-E3 ligase activity was found in the RING domain 
of the TRIM5δ isoform (Xu et al. 2003), the RING finger domain of TRIM5α might also 
confer similar activity. It was shown that the rapid turnover of the TRIM5α protein 
itself is likely mediated via auto-polyubiquitination of the RING domain followed by 
proteasomal degradation (Diaz-Griffero et al. 2006). To what extent (if at all) 
ubiquitin-conjugating activity is necessary for retroviral restriction still needs to be 
elucidated. However, two reports suggest that proteasomal degradation plays an 
important role during TRIM5α restriction. The authors of these papers showed that 
proteasomal inhibition preserves the overall restriction activity of rhTRIM5α or 
huTRIM5α but uncouples the reverse transcription block, leading to formation of 
functional, but still restricted preintegration complex intermediates (Anderson et al. 
2006; Wu et al. 2006).  
The RING finger following, the Bbox-2 domain, a motif exclusively found in the TRIM 
family of proteins, forms an additional zinc finger by binding one zinc atom via 
conserved cysteine and histidine residues. In general, the function of B-boxes 
remains unknown. However, in contrast to mutations within the RING domain, 
deletion of both RING and Bbox-2 as well as mutation of the zinc-coordinating 
residues in the B-box-2 motif caused a complete loss of antiviral activity (Perez-
Caballero et al. 2005a; Javanbakht et al. 2005), indicating an essential role during 
restriction.  
The adjacent coiled-coil motif is a typical hyper-secondary structure (formed by 
intertwining of multiple α-helices) and is thought to mediate homo- and hetero-
interactions between TRIM molecules (Reymond et al. 2001). Cross-linking studies 
revealed that TRIM5α exists as a trimer (Mische et al. 2005), a conformation which is 
suggested to be necessary for retroviral capsid binding (Javanbakht et al. 2006). 
Deletion of the coiled-coil motif completely abrogates the restriction activity of 
TRIM5α.  
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B. General aim of the study 
Novel and improved transient expression methods for many approaches in gene 
therapy, biotechnology or basic science are of great interest. Retroviruses are 
evolutionary optimized and adapted to the host´s cellular machinery, which makes 
them interesting candidates for the transient and therefore reversible expression of 
transgenes. Since conventional retroviral gene delivery results in stable transgene 
expression, the generation of vector particles which are defective for either reverse 
transcription or integration are necessary. Introduction of specific mutations within the 
retroviral vector genome or the Gag/Pol expression construct may allow the inhibition 
of specific steps (depending on the type of the introduced mutation) within early 
phases of the retroviral life cycle. An already existing transient retroviral expression 
method is the use of integrase-deficient lentiviral vector particles, where specifically 
introduced point mutations within the catalytic core domain of the lentiviral integrase 
(e.g. D64V point mutation within the DDE motif) result in the formation of non-
integrating episomal lentiviral DNA molecules. However, one undesirable side effect 
is the potential of residual integration events of these episomal DNA molecules 
(Nightingale et al. 2006). 
Infectious virions of retroviruses contain two copies of their plus-stranded RNA 
genome. Retroviral RNA genomes are equipped with a 5´ Cap structure and a 3´ 
PolyA-tail, and therefore highly resemble cellular messenger RNAs. Thus, when 
reverse transcription is disabled, retroviral particles might serve as an interesting 
mRNA delivery tool for a receptor-mediated, transient, and ectopic expression of 
proteins in target cells. Thus, one could generate reverse transcription-deficient 
vector particles that - after receptor-mediated uptake and the retroviral uncoating 
process – release their genomic vector mRNA (encoding for the transgene of 
interest) into the cytoplasm for translation. The contents of the following publications 
are based on this hypothesis. 
The aim of publication 1 was the generation and comparison of MLV-based vector 
mutants that are deficient in reverse transcription and/or integration. As a paradigm, 
these mutants were tested for their capability to mediate transient transfer of the site-
specific recombinase Cre into human and mouse fibroblasts.  
The second publication focussed on mechanisms underlying “retroviral particle-
mediated mRNA transfer” (RMT) and how it might be limited by cellular restriction 
factors. The sensitivity of RMT to shRNAs and retroviral restriction factors 
(huTRIM5α and Fv1) were explored in this work.  
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Self-inactivating (SIN) retroviral vectors were designed to lack U3 enhancer/promoter 
sequences of their LTRs after proviral integration, and therefore transcription of the 
transgene is initiated by an internal promoter (Yu et al. 1986). However, in contrast to 
corresponding lentiviral packaging systems, packaging of gammaretroviral SIN 
vectors suffers from suboptimal titers (Yu et al. 1986; Ailles and Naldini 2002). Thus, 
the topic of publication 3 was to understand the mechanism underlying titer reduction 
and to improve gammaretroviral SIN vector packaging by introducing stronger 5’ 
enhancer/promoter sequences within the retroviral vector plasmid. In line with this 
study, we investigated whether the improved 5’ enhancer/promoter sequences could 
also enhance RMT (supplementary figure 1).  
These three studies show that the retroviral genomic RNA of gammaretroviral vector 
particles may serve as a translation template when reverse transcription is disabled 
and that this type of modified vector particles may be a potential tool for targeted and 
transient cell modification.  
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Retroviral Pseudotransduction for Targeted Cell Manipulation 
Melanie Galla, Elke Will, Janine Kraunus, Lei Chen and Christopher Baum 
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a. Abstract 
The present study addressed whether retroviral vectors could be modified to achieve 
receptor-mediated, dose-controlled, and transient delivery of proteins or nucleic acids 
into targeted cells. As a paradigm, we generated mouse leukemia virus-based 
vectors encoding the site-specific recombinase Cre. The vectors were disabled in 
primer binding site function, blocking reverse transcription of the virion mRNA. While 
reducing transgene insertion more than 1000-fold and abolishing toxic effects of 
constitutive Cre expression, transient Cre delivery was still highly efficient, receptor-
restricted, and insensitive to pharmacologic inhibition of reverse transcription. This 
form of Cre transfer required the retroviral packaging signal, cap-proximal positioning 
of the translation unit, as well as gag and env expression in producer cells, revealing 
retroviral mRNA transfer as the underlying mechanism. Thus, retrovirally delivered 
mRNA may serve as an immediate translation template if not being reverse 
transcribed. This approach allows multiple modifications for targeted and reversible 
cell manipulation with nucleic acids. 
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b. Introduction 
Numerous applications of advanced cell biology and cellular therapy would profit 
from the development of new methods for targeted and reversible delivery of protein 
or mRNA. Retroviruses infect cells through receptor-mediated uptake, reversely 
transcribe plus-stranded genomic mRNA into double-stranded proviral DNA, and 
integrate the proviral copy into the host genome. Thereafter, spliced and unspliced 
proviral mRNA is transcribed, the latter being specifically packaged into novel 
retroviral particles. Retroviral pseudotransduction has been described as a process 
that may lead to the expression of foreign proteins, without delivering integrating 
proviral DNA (Haas et al., 2000; Nash and Lever, 2004). Previously, this 
phenomenon has not been exploited to exert specific biological functions. Here we 
show that retroviral particles can be manipulated for targeted delivery of mRNA, 
resulting in efficient transient cell manipulation. Proof of principle is established with 
transfer of Cre recombinase.  
The bacteriophage endonuclease Cre excises double-stranded DNA flanked by loxP 
recognition sites from the genome of prokaryotic or eukaryotic cells. Cre may thus 
reverse a specific transgene insertion, or also trigger site-specific insertion of a 
transgene into a single loxP site. Cre represents a member of a larger family of site-
specific endonucleases that are of great interest for experimental and therapeutic cell 
manipulation (Ghosh and Van_Duyne, 2002; Gorman and Bullock, 2000). 
Constitutive expression of Cre is genotoxic, and therefore, reversible delivery of Cre 
as a recombinant protein (“protein transduction”) or from self-excising retroviral 
vectors has been developed (Jo et al., 2001; Loonstra et al., 2001; Peitz et al., 2002; 
Pfeifer et al., 2001; Silver and Livingston, 2001; Will et al., 2002). However, 
transduction of recombinant Cre protein does not allow targeting to a specific cell 
type in a mixed population, and retroviral self-excision may still disrupt cellular genes 
or trigger translocations with loxP sites present in the targeted allele or in another 
integrated provirus copy.  
 
c. Results 
Design of retroviral vector mutants 
To investigate the potential of retroviral pseudotransduction for delivery of Cre, we 
inserted a nuclear localizing variant of Cre (nlsCre) into mouse leukemia virus (MLV) 
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based retroviral vectors that mediated stable integration into the target cell genome 
(SF91-nlsCre, Figure 1A). To inhibit stable gene transfer, we designed several 
mutants. Vector dPBS lacks the retroviral primer binding site (PBS) to disable reverse 
transcription (RT) into proviral DNA. Vector aPBS contains an artificial PBS that 
cannot prime RT unless being complemented by a recombinant tRNA (Lund et al., 
1997). Vector dU5 contains all elements required for RT into double-stranded DNA 
but lacks the att recognition motif of the retroviral integrase (Basu and Varmus, 
1990), along with flanking sequences of the U5 region (Figure 1A).  
 
Mutations strongly inhibit stable retroviral gene delivery 
Experiments with retroviral vectors expressing enhanced green fluorescent protein 
(EGFP) revealed that all three mutants transiently expressed high levels of EGFP 
after physicochemical transfection into retroviral packaging cells. Ecotropic particles 
of the intact retroviral vector SF91-EGFP mediated stable gene transfer with a titer of 
~106 infectious particles per milliliter of unconcentrated supernatant. Using 
concentrated supernatants of SF91-EGFP on NIH3T3, 50% of cells were stably 
transduced (Figure 1B). Under identical experimental conditions, supernatants of 
packaging cells transfected with mutants dU5-EGFP, aPBS-EGFP and dPBS-EGFP 
were at least 1000-fold attenuated in their capacity of stable gene transfer (Figure 
1B).  
 
Retroviral pseudotransduction occurs immediately after particle exposure 
The process of retroviral receptor binding, particle uptake, nuclear transport, 
integration, and de novo transcription of mRNA requires several hours. By flow 
cytometric detection of EGFP, we investigated the kinetics of retroviral 
pseudotransduction (Figure 1C). Starting 5 hr until 13 hr after exposure, SF91-EGFP 
and aPBS-EGFP mediated an equal, weak but significant increase of EGFP 
expression when compared with control cells. Culminating between 13 and 55 hr, 
SF91-EGFP mediated a >60-fold higher fluorescence intensity than the peak level 
observed with aPBS-EGFP, which started to decline 19 hr after exposure. These 
data indicate that the early phase after exposure (5-13 hr) was dominated by 
pseudotransduction activity, irrespective of the vector’s capacity to undergo RT and 
integration. If, however, stable delivery of retroviral DNA occurs, de novo transcription 
results in a much higher expression of the encoded gene, depending on the strength 
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of the vector. The persistence of EGFP fluorescence until 36h after exposure to 
aPBS particles is best explained by the long half-life of the encoded protein.  
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Retroviral mutants deliver Cre activity with high efficiency 
To detect the ability of retroviral particles to transfer nlsCre into target cells, we used 
mouse and human fibroblasts as indicator cells. These contained a reporter allele 
SFr-2 in which loxP-flanked coding sequences of red fluorescent protein (DsRed2) is 
deleted and transcription of EGFP is initiated only following Cre exposure (See 
Supplemental Figure 1 at http://www.molecule.org/cgi/content/full/16/2/309/DC1) (Will 
et al., 2002). 
 
               
 
As judged by the conversion to the EGFP+ phenotype all retroviral mutants mediated 
efficient and dose-dependent Cre activity in target cells (Figure 2A). Cre-mediated 
induction of EGFP expression was most efficient when using as vehicle retroviral 
particles of mutants aPBS-nlsCre. The potency of the cellular supernatants showed 
some variability possibly due to differences in the transfection efficiency of the 
producer cells. Therefore, comparative experiments were performed with 
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supernatants from virus productions performed in parallel under identical conditions. 
Using the most potent preparations, almost complete conversion of the target cell 
population could be achieved with a single treatment, even with unconcentrated 
supernatants (Figure 2B). 
 
Cre delivery by retroviral mutants is transient and not toxic 
Importantly, prolonged analysis of uncloned target cells after exposure to retroviral 
Cre supernatants revealed that mutant aPBS-nlsCre did not induce any overt target 
cell toxicity, whereas cells harboring integrating retroviral vectors encoding Cre were 
counterselected, likely due to genotoxic side effects of persistent Cre expression 
(Loonstra et al., 2001; Pfeifer et al., 2001; Silver and Livingston, 2001). To 
demonstrate this important advantage of retroviral pseudotransduction, we started 
with populations of target cells where EGFP expression was achieved with 80%-96% 
efficiency using the integrating retroviral vector SF91-nlsCre. The frequency of 
EGFP+ cells decreased by 45% within 22 days. In contrast, using aPBS-nlsCre the 
frequency of EGFP+ cells remained constant, independent of the initial Cre load 
(Figure 2B). Detection of Cre by Western blot and of Cre encoding DNA by PCR 
revealed counterselection of cells with persistent Cre expression following use of 
SF91-nlsCre or dU5-nlsCre, but not aPBS-nlsCre (Figures 3A and 3B).  
Physicochemical transfection and adenoviral vectors may be considered as 
alternative procedures for transient Cre delivery. With either method, a high efficiency 
of Cre transfer was achieved. Comparing similar populations with 50%-70% of 
reporter cells in which Cre had been active, we found that adenovirally transduced 
cells were counterselected with similar kinetics as cells transduced with the 
integrating retroviral vector SF91-nlsCre (Supplemental Figure 2A). This could be 
explained by persisting nlsCre expression from episomal adenoviral transgenes. 
Cells physicochemically transfected with a Cre plasmid were not significantly 
counterselected but the overall toxicity was very high, probably due to the 
transfection reagent (Supplemental Figure 2B). Under identical conditions, aPBS-
nlsCre neither caused counterselection nor general toxicity, leading to an 8-10x 
higher recovery of cells 2 days after exposure. 
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Pseudotransduction depends on retroviral particle assembly and mRNA 
packaging  
Controls addressed which retroviral components were required for transfer of Cre 
activity by constructs aPBS-nlsCre and dPBS-nlsCre. No evidence of Cre delivery 
was observed when omitting either of the three key components of the retroviral 
packaging process (Gorelick et al., 1988): the gag-pol expression plasmid, the env 
expression plasmid, or the retroviral packaging signal (Ψ) of the Cre plasmid. The 
latter construct encoded large amounts of Cre mRNA and protein in transfected 293T 
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cells (data not shown). However, uptake of a cellular mRNA lacking Ψ into retroviral 
particles is expected to be very inefficient (Gorelick et al., 1988). The latter control 
also excluded passive protein transfer and contamination of retroviral particles by 
transfected plasmid DNA as the underlying mechanisms of Cre transfer by dPBS or 
aPBS (Chen et al., 2001; Will et al., 2002). Thus, retroviral pseudotransduction 
requires retroviral particle formation with incorporation of Ψ+mRNA and an active 
retroviral infection process triggered by Env. The retroviral mRNA must be able to 
serve as an immediate translation template if not undergoing RT. In line with this 
hypothesis, pseudotransduction with mutant dPBS was impossible when expressing 
Cre from an internal promoter located 3’ of Ψ on the retroviral mRNA (data not 
shown). In this case, cap-dependent ribosomal scanning could only occur after de 
novo synthesis of mRNA in transduced cells.  
Further evidence for the role of Ψ+mRNA in retroviral pseudotransduction was 
obtained when inhibiting RT in target cells with 3´-Azido-3´-deoxythymidine (AZT) 
(Strair et al., 1991). This drug inhibited stable EGFP transfer by the intact vector 
SF91-EGFP in a highly efficient manner (Supplemental Figure 3). As expected, 
residual pseudotransfer leading to a weak shift of cellular fluorescence was still 
observed. However, while nlsCre delivery by the vector aPBS-nlsCre was completely 
insensitive to AZT, Cre delivery by the intact vector SF91-nlsCre was reduced by up 
to 50%  (Supplemental Figure 3). This suggested that pseudotransduction of intact 
retroviral vectors may not be as efficient as that of RT deficient mutants. 
 
Retroviral pseudotransduction allows targeting of specific cells 
Finally, to address whether transfer of Cre activity by aPBS-nlsCre was receptor-
mediated, we mixed human HT1080 and murine Sc-1 cells carrying the same 
indicator allele SFr-2. EGFP conversion was restricted to murine cells when using 
ecotropic supernatants. In contrast, use of the RD114 Env largely restricted Cre 
transfer to human cells (Figure 4). Even when human cells represented a minor 
population (<5%), specific targeting with RD114 enveloped particles containing 
aPBS-nlsCre was possible (data not shown). The data are consistent with the known 
species restriction of these pseudotypes (RD114 may confer residual infectivity in 
mouse cells [F.L. Cosset, personal communication]) (Hanawa et al., 2002). As 
expected, the tropism was independent of the type of vector used (SF91 or PBS or 
dPBS). 
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d. Discussion 
By delivering Cre recombinase, we demonstrate here that retroviral pseudo-
transduction can be exploited for highly efficient, dose-controlled, transient, and 
targeted manipulation of specific cells in a mixed population. Introducing mutations in 
the PBS or U5 region of the retroviral mRNA resulted in an up to 10,000-fold 
reduction of stable gene transfer efficiency while still mediating sufficient Cre delivery 
for site-specific recombination in up to 95% of exposed cells. Our study demonstrates 
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that receptor-mediated uptake of retroviral particles serves the key mechanism of 
retroviral pseudotransduction, strongly arguing against a major role of cellular 
microvesicles or transfected plasmid DNA which may contaminate producer cell 
supernatants. After receptor-mediated entry, it is formally possible that retroviral 
pseudotransduction depends on transient delivery of RNA, protein and/or episomal 
DNA. 
 
Retroviral pseudotransduction after blockade of integrase function 
When using the dU5 mutant, in which crucial cis-regulatory elements required for RT 
are preserved (PBS, R region and polypurine tract), double-stranded DNA may still 
be formed and transported to the nucleus. As the deletion of the U5-located att 
recognition motif inhibits the function of the retroviral integrase (Basu and Varmus, 
1990), a strong reduction of stable transgene insertion by this mutant was expected. 
A deletion of the second att motif in the U3 region and structural or pharmaceutical 
blockade of the retroviral integrase may allow even more stringent retroviral delivery 
of unintegrated DNA. A recent report suggests that such a version of retroviral 
pseudotransduction may allow transient or semipermanent de novo RNA synthesis 
(Vargas et al., 2004). However, this form of pseudotransduction bares a residual risk 
of stable transgene insertion and unpredictable duration of transgene expression. 
 
Retroviral pseudotransduction after blockade of RT 
When using mutants aPBS or dPBS, in which the initiation of RT is severely disabled 
(Lund et al., 1997), retroviral pseudotransduction must be dependent on “early 
translation” of the retroviral mRNA, and/or on passive transfer of proteins in retroviral 
particles (Supplemental Figure 4). However, retroviral particles are not expected to 
uptake major non-retroviral protein cargo except that specific domains are present 
which direct an interaction with gag proteins or proviral RNA. Such a process may 
result in uptake of inhibitory cellular proteins such as APOBECG3 or accessory viral 
proteins such as Vif (KewalRamani and Coffin, 2003). Using highly concentrated 
supernatants of lentiviral vector preparations pseudotyped with the cytotoxic 
glycoprotein of vesicular stomatitis virus, Nash and Lever (2004) recently reported 
transient EGFP protein transfer into target cells. However, in this study microvesicels 
and cellular debris may also have contributed to the EGFP transfer, raising concerns 
regarding the specificity of the method for practical use.  
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In the present study, several controls indicated that passive delivery of (nuclear 
localizing) Cre protein does not explain pseudotransduction by any of the mutants 
tested here. Pseudotransduction was only possible when the Cre-encoding RNA 
contained the retroviral Ψ signal and when the Cre translation unit was accessible by 
a cap-dependent scanning process. mRNAs in which Cre was encoded from an 
internal promoter located downstream of Ψ were inefficient in this process. Finally, 
experiments with AZT showed that the characteristic RT step of retroviruses is not 
necessary for this form of pseudotransduction, and therefore, the term “retroviral” 
may even be somewhat misleading. In a broader sense, we suggest this 
phenomenon be addressed as retroviral particle-mediated mRNA transfer (RMT), 
leading to “early translation” of the encoded proteins after particle disassembly. This 
process may also be exploited when using other viruses with a genomic plus-
stranded mRNA (such as picornaviridae) (Wilson, 1985).  
Our study revealed that RMT occurred in the first hours after exposure of cells to 
retroviral particles. As these contain just two strands of mRNA, it seems plausible 
that the efficiency of RMT depends on the substantial excess of infectious particles 
over integration events (McDonald et al., 2002). Our data suggest that following 
uptake in the cytoplasm, many retroviral particles will not undergo RT but rather 
disassemble to release their genomic RNA for subsequent translation (Supplemental 
Figure 4). While this process is likely to represent a dead end of retroviral replication, 
it is not expected to be hindered by postentry defense mechanisms targeting 
downstream steps of RT or nuclear translocation (Besnier et al., 2003; KewalRamani 
and Coffin, 2003; Towers and Goff, 2003) and, therefore, should be cell-cycle 
independent even when using gammaretroviral particles. 
 
Developing pseudotransduction as a method for cell manipulation 
Following these considerations, it may be possible to adapt gammaretroviral RMT to 
applications with increased potency requirements by supernatant concentration, 
particle preloading, or repetitive exposure. It may also be possible to manipulate the 
disassembly process to increase the efficiency. Additional mutations of the 
transferred mRNA or the retroviral pol functions are expected to completely avoid 
residual RT and DNA integration. The major advantage of the method is the potential 
to avoid DNA transfer while still introducing specific mRNA, in a receptor-mediated 
manner. Of note, envelope modifications are not only useful for retargeting of 
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retroviral particles to defined subsets of cells, such as human T lymphocytes or 
cancer cells (Schnierle et al., 1997; Chowdhury et al., 2004); they might also allow a 
combination of RMT with delivery of growth factor signals (Verhoeyen et al., 2003). In 
general, we expect RMT to be particularly useful for applications where relatively low 
and transient expression of proteins may lead to striking biological effects: examples 
are the expression of receptors involved in homing of circulating cells, transcription 
factors, or cellular proteins regulating cell expansion and differentiation, and, as 
exemplified by Cre, recombinases or integrases for targeted genetic interventions. 
 
e. Experimental Procedures 
Cre reporter cell lines 
Murine and human fibroblast lines containing a Cre reporter allele were generated by 
transducing Sc-1 (ATCC CRL-1404) and HT1080 (ATCC CCL-121) with the retroviral 
vector SFr-2, containing DsRed2 cDNA flanked by loxP sites. Clones expressing 
DsRed2 were obtained by single cell sorting. SFr-2 is a derivate of SFr (Will et al., 
2002) encoding DsRed2 instead of DsRed1 and the woodchuck hepatitis B virus 
posttranscriptional regulatory element (Schambach et al., 2000).  
 
Retroviral vectors and plasmids 
Retroviral vector SF91-nlsCre was derived from SF91-EGFP (Schambach et al., 
2000) by replacing an EGFP NcoI-NheI fragment with a NcoI-NheI fragment of 
pGEX-nlsCre (Will et al., 2002). Mutant vectors lacking the U5 region of the 5’LTR 
located 70-145 bp downstream of the CAP site (SF91dU5-EGFP) or lacking the PBS 
located 146-163 bp downstream of the CAP site (SF91dPBS-EGFP) were derived 
from SF91-EGFP by overlapping PCR, resulting in precise deletions. Corresponding 
vectors SF91dU5-nlsCre and SF91dPBS-nlsCre were obtained by replacing the 
EGFP NcoI-NheI fragment with a NcoI-NheI fragment of pGEX-nlsCre (Will et al., 
2002). In SF91aPBS-EGFP, sequences 149-160 bp downstream of CAP were 
replaced by TCAGCTGCAGGG using site-directed mutagenesis, according to Lund 
et al. (1997). Correct deletions or nucleotide replacements were confirmed by 
sequencing. The eukaryotic Cre expression plasmid pCMVnlsCre lacking Ψ was 
generated by replacing the EGFP cDNA in pEGFP-C1 (Clontech, Heidelberg, 
Germany). 
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Production of retroviral particles 
Packaging of SFr-2, SF91-nlsCre, SF91dU5-nlsCre, SF91dPBS-nlsCre and 
SF91aPBS-nlsCre in retroviral particles was performed by cotransfection of the 
retroviral plasmid with expression plasmids for MLV gag-pol and either ecotropic 
(Morita et al., 2000) or RD114 envelopes (Cosset et al., 1995) into Phoenix GP (G. 
Nolan, Stanford University, Palo Alto, CA) or 293T cells. Transfection, harvest and 
concentration of virus-containing supernatants was performed as described 
previously (Beyer et al., 2002). 
 
Cell culture and transduction 
293T, Phoenix-GP, NIH3T3, Sc-1, and HT1080 cells were grown in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% FCS. The day before 
transduction 5 x 104 cells were plated. 1 ml undiluted or serial dilutions of retroviral 
supernatants were applied to the cells. Transduction was assisted by adding 4 µg/ml 
protamine sulfate and centrifugation for 60 min at 400 x g and 25ºC-32°C. After 2 
days the percentage of EGFP+ cells was analyzed by FACS. For specific detection of 
human cells, mixed populations were stained with anti human HLA(A,B,C)-APC 
conjugate (BD Pharmingen, San Diego, CA). 
 
Lipofection and adenoviral gene transfer 
105 reporter cells were seeded 12 hr before treatment. Transfection with pCMVnlsCre 
was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the 
manufacturer´s instructions. Cells were washed with PBS and incubated with a 
mixture of 1 µg pCMV-nlsCre with either 1, 2 or 3 µl Lipofectamine in a total volume 
of 200 or 400 µl Opti-MEM I (Gibco, Grand Island, NY) containing no or 5% FCS for 5 
or 12 hr. Standard culture conditions were used until FACS analysis. 
AdCreM2 supernatants (Microbix, Toronto, Canada) were produced according to the 
manufacturer’s instructions. Cells were incubated for 1 hr at 37°C with 0.5 to 40 µl of 
AdCreM2 supernatant in a total volume of 200 µl PBS/4 % FCS. Cells were washed 
twice with PBS, and cultivated as above. 
The percentage of dead cells and cells targeted by Cre (EGFP+) was determined by 
FACS analysis after staining with 7AAD (BD Pharmingen). 7AAD+ events and events 
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with low forward scatter were considered to be dead cells (verified by Trypan blue 
staining). 
 
Western blot 
Cell lysates were obtained after 15 min incubation with 50µl RIPA buffer containing 
proteinase inhibitors (Complete, Roche, Indianapolis, IN). Samples were separated 
by SDS/PAGE(12.5%), transferred to nitrocellulose membranes (Bio-Rad, Hercules, 
CA), and probed with anti-Cre (Novagen, Madison, WI) 1:7,000 or anti-GFP (Santa-
Cruz, Santa Cruz, CA) antiserum 1:500 in TBST/3% dry milk. The secondary 
antibody anti-rabbit-HRP (Santa Cruz) was used at a 1:10,000 dilution in TBST/3% 
dry milk. Detection was carried out by chemiluminescence (ECL, Pierce, Rockford, 
IL).  
 
Semiquantitative PCR  
Genomic DNA was isolated 9 or 22 days post transduction with QIAamp DNA Blood 
Mini Kit (Qiagen, Valencia, CA) after the manufacturer’s protocol. 500 ng of DNA was 
used for PCR amplification of Cre DNA sequence using oligonucleotides 
GGTGAACGTGCAAAACAGGCTCTA and GCTTGCATGATCTCCGGTATTGAAA. 
PCR was performed using Taq polymerase (New England Biolabs, Beverly, MA), 2 
min 94°C, followed by 41 cycles of 30 s at 94°C, 30  s at 57°C, and 40 s at 72 °C. For 
the control amplification of EGFP-wPRE oligonucleotides ACGAGAAGCGCGATCAC 
ATGGTCCTG and CCAAATCAAGAAAAACAGAACAAATA were used under iden-
tical conditions.  
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a. Abstract 
Analyzing cellular restriction mechanisms provides insight into viral replication 
strategies, identifies targets for antiviral drug design, and is crucial for the 
development of novel tools for experimental or therapeutic delivery of genetic 
information. We have previously shown that retroviral vector mutants that are unable 
to initiate reverse transcription mediate a transient expression of any sequence which 
replaces the gag-pol transcription unit, a process we call retrovirus particle-mediated 
mRNA transfer (RMT). Here, we further examined the mechanism of RMT by testing 
its sensitivity to cellular restriction factors and shRNAs. We found that both human 
TRIM5α and, to a lesser extent Fv1, effectively restrict RMT if the RNA is delivered 
by a restriction-sensitive capsid. While TRIM5α restriction of RMT led to reduced 
levels of retroviral mRNA in target cells, restriction by Fv1 did not. Treatment with the 
proteasome inhibitor MG132 partially relieved TRIM5α-mediated restriction of RMT 
but not TRIM5α-mediated restriction of wild-type integrating vectors. Finally, cells 
expressing shRNAs specifically targeting the retroviral mRNA, inhibited RMT 
particles, but not reverse-transcribing particles. Retroviral mRNA may thus serve as a 
translation template if not used as a template for reverse transcription. Our data imply 
that retroviral nucleic acids become accessible to host factors, including ribosomes, 
as a result of particle remodeling during cytoplasmic trafficking.  
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b. Introduction 
Retroviruses enter cells in a receptor-mediated manner, following which a reverse 
transcription (RT) complex is formed in the cytoplasm to reverse transcribe the 
genomic mRNA into double-stranded DNA. During the completion of RT, a hybrid 
virus-cellular nucleoprotein structure known as the preintegration complex (PIC) is 
formed. Eventually, active transport of the PIC into the nucleus or dissolution of the 
nuclear membrane during mitosis allows the viral integrase to integrate the viral 
double-stranded DNA into chromosomal cellular DNA (35). We have previously 
shown that retroviral vector mutants that are unable to initiate RT of their capped, 
plus-stranded mRNA genomes mediate a transient expression of the sequences 
cloned into the gag-pol equivalent position of the vector genome (8). Particles 
conferring this activity required the presence of the retroviral mRNA packaging signal 
within the vector sequence as well as the expression of both Gag and Env in the 
vector packaging cell, but not reverse transcriptase. We refer to this previously 
unexplored aspect of the retroviral life cycle as retrovirus particle-mediated mRNA 
transfer (RMT). Using replication-defective retroviral vectors in which the gene of 
interest is cloned in the position of the gag reading frame, RMT can be exploited as a 
novel approach for the transient expression of a gene of interest (8).  
The analysis of cellular restriction factors that belong to the innate immune response 
against retroviruses may provide further insights into the mechanisms of RMT. The 
cellular restriction factor Fv1 (Friend virus susceptibility factor 1) has been shown to 
impact on the sensitivity of mice to murine leukemia viruses (MLV) (17). Further 
studies identified two major alleles of Fv1. Whereas the Fv1n allele confers resistance 
to B-tropic MLV (B-MLV), but not N-tropic (N-MLV), infection in NIH mice, Fv1b 
renders BALB/c mice resistant to N-MLV but susceptible to B-MLV infection (3, 9). 
The differences in N- and B-MLV infectivity are due to a single amino acid residue at 
position 110 (arginine and glutamic acid, respectively) in the retroviral capsid. The 
exact mechanism of action of Fv1 remains to be elucidated. 
Another retroviral restriction factor is the cytoplasmic body component TRIM5α, a 
member of the tripartite motif family of proteins (TRIM) (10, 14, 24, 33, 40). As a 
defining feature of TRIM proteins, TRIM5α harbors an RBCC motif, which consists of 
a RING (“Really Interesting New Gene”) domain at the N-terminus followed by a B- 
box-2 domain and a coiled-coil domain (25). The C-terminal domain of TRIM5α is a 
B30.2 or PRY/SPRY domain, whose amino acid sequence confers the specificity of 
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retroviral restriction (28, 32, 34, 41). Whereas rhesus monkey TRIM5α has the ability 
to restrict human immunodeficiency virus type 1, human TRIM5α (huTRIM5α) 
restricts N-MLV, but not B-MLV infection (40). Interestingly, as for Fv1, the same 
amino acid residue at position 110 within the retroviral capsid controls susceptibility 
to TRIM5α restriction (24, 36). However, although Fv1 and huTRIM5α seem to 
interact with the retroviral capsid at an early postentry step, the mechanism of 
restriction appears to differ. huTRIM5α usually acts before RT, whereas Fv1 allows 
RT, but blocks subsequent steps including integration into the host genome (2, 7, 12, 
21, 36, 37). 
In the present study, we examined the sensitivity of RMT to cellular restriction factors 
and short hairpin RNA (shRNA). We found that RMT is sensitive to restriction by both 
huTRIM5α and Fv1. The restriction of RMT by huTRIM5α could be partially relieved 
by the proteasome inhibitor MG132. Interestingly, the restriction of RMT by 
huTRIM5α, but not by Fv1, correlated with the degradation of the retroviral genomic 
RNA in the cytoplasm of infected cells. shRNAs specifically targeting the retroviral 
genomic RNA inhibited RMT but did not interfere with reverse-transcribing particles. 
These observations shed new light on the cytoplasmic fate of nucleic acids contained 
in retroviral particles. 
 
c. Results 
Kinetics of RMT vectors in comparison with those of non-integrating lentiviral 
episomes 
As a first step to elucidate the mechanisms underlying RMT, we compared the 
kinetics of gene expression after RMT, the delivery of episomal lentiviral (eLV) DNA 
or transduction with integrating gammaretroviral (iRV) or integrating lentiviral (iLV) 
vectors encoding enhanced green fluorescent protein (EGFP). All vectors contained 
the woodchuck hepatits virus post-transcriptional regulatory element (wPRE) for the 
optimization of titers and RNA processing (42). The RMT vector SF91aPBS.GFP.pre 
encodes EGFP downstream of the splice acceptor sequence (Fig. 1A). RT was 
blocked by the presence of an artificial primer binding site (aPBS) that does not 
correspond to any cellular tRNA (18). RT is therefore possible only if the 
corresponding tRNA is cotransfected into packaging cells (8, 18). In the present 
study, we used a vector with a PBS for the tRNAGln as the integration-competent 
control (SF91.GFP.pre). We also produced a third-generation self-inactivating 
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lentiviral vector (RRL.PPT.SF.GFP.pre) expressing EGFP under the control of the 
strong enhancer-promoter derived from the long terminal repeat of the MLV spleen 
focus-forming virus (SFFV). Additionally, integration-defective lentiviral particles, 
competent to form episomal DNA by using an integrase-deficient variant of the 
lentiviral gag-pol plasmid (integrase D64V) were produced (20, 26).  
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In this set of experiments, all vector particles were pseudotyped with the glycoprotein 
from vesicular stomatitis virus (VSVg). Using a high multiplicity of infection (MOI), we 
transduced SC-1 fibroblasts with these four different vector preparations: 
SF91aPBS.GFP.pre for RMT, RRL.PPT.SF.GFP.pre+D64V for delivery of episomal 
lentiviral DNA, RRL.PPT.SF.GFP.pre packaged with intact lentiviral gag-pol for 
delivery of integrating lentiviral vectors, and SF91.GFP.pre for delivery of integrating 
gammaretroviral vectors. All integrating vectors were used at an MOI of 10. EGFP 
expression was monitored by flow cytometry at regular intervals, starting 7 h after 
transduction and ending after 10.5 days. Mock-transduced cells served as negative 
controls.  
This side-by-side comparison of the kinetics of the expression of EGFP revealed that 
RMT particles, which are RT-deficient retrovirus mutants containing EGFP vector 
RNA (18), express EGFP for a relatively short duration and to a low level (Fig. 1B). 
The peak of EGFP expression was 1 order of magnitude above background 
fluorescence and occurred 24 h after transduction. The continuous decay to 
background levels until day 6.5 is consistent with the half-life of EGFP (6). There was 
no evidence for residual integration events following the use of aPBS vectors, 
consistent with earlier reports (8, 18). After transduction with the episomal or 
integration-competent vectors, the peak of expression occurred later (day 2) and 
reached much higher levels: 3 orders of magnitude above background with the 
integration-defective vector and saturating levels with the integrating vectors. While 
expression remained stable over the observation period with both integrating vectors, 
EGFP expressed from the integration-defective lentiviral vectors decayed within 8 
days but did not return to background levels. Continued expression in more than 1% 
of the target cell population was suggestive of residual integration events, as 
previously described (Fig. 1C) (20). The residual integration of the D64V mutant may 
be circumvented by using a double or triple mutant at the DDE catalytic site. 
These data show that two important features distinguish RMT from other forms of 
retroviral delivery of genetic information (episomal or integrated DNA): the relatively 
low levels of expression and the complete reversion to background levels.  
 
Characterization of RMT particles and wild-type viral particles  
The aPBS within RMT vectors was designed not to match any naturally occurring 
tRNA molecule (18); therefore, the retroviral genomic RNA is packaged without the 
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primer for initiation of RT. To address the possibility that these modifications could 
affect the biochemistry of this type of viral particle, we compared viral RNA content, 
reverse transcriptase activity, capsid (p30) load and biological titers of RMT versus 
wild-type (iRV) retroviral supernatants (Fig. 2; Table 1). For this analysis, we 
packaged SF91.nlsCre (iRV) and SF91aPBS.nlsCre vectors (RMT), which are similar 
to the GFP vectors described above (Fig. 1A) but harbor the nlsCre cDNA instead 
and do not contain the wPRE. For each vector type (iRV and RMT vector), we 
analyzed four different retroviral preparations (B- and N-tropic, VSVg, and ecotropic 
pseudotypes). After harvest, the supernatants were concentrated via ultracentri-
fugation and the obtained pellets resuspended in phosphate buffered saline for 
further analysis. The retroviral genomic RNA contents of the supernatants were 
determined via real-time PCR (Table 1). In all samples, DNA contamination were 
excluded. Table 1 shows a clear correlation between the biological titer of a retroviral 
supernatant and its retroviral genomic RNA content (R2 = 0.99 for RMT supernatant 
and R2 = 0.89 for iRV supernatant). In the case of RMT vector, the strict correlation of 
retroviral genomic RNA content and titer suggests that the biological activity is 
entirely mediated by packaged RNA, whereas in the case of iRV, subsequent steps 
of RT, integration and de novo transcription contribute to the biological activity.  
 
  
 
Importantly, comparison of the same pseudotypes (ecotropic and VSVg), revealed 
that the reverse transcriptase activity (Table 1; Fig. 2) were similar for iRV and RMT 
particles but did not correlate as nicely as the retroviral genomic RNA content with 
the biological titer. Furthermore, Western blot analysis of the retroviral supernatants 
used for the experiments whose results are shown in Table 1 revealed comparable 
capsid (p30) and Gag precursor protein (p65) levels for RMT and iRV particles (Fig. 
  Publication 2    57   
     
2). We conclude that RMT particles have a composition similar to that of iRV 
particles, a conclusion which is supported by the results of previous studies 
demonstrating that MLV particle assembly occurs independently of the packaged 
retroviral RNA (19, 16). 
 
                         
 
RMT is restricted by inhibitory RNA expressed in target cells 
The above results and our previously published experiments provide indirect 
evidence for the mechanisms underlying RMT (8). Further supporting the hypothesis 
that genomic RNA containing the packaging signal mediates the biological activity of 
RMT, we found that RMT activity depends on the amount of unspliced RNA 
expressed in packaging cells, whereas high expression of spliced, subgenomic RNA 
did not contribute to RMT activity (data not shown). To directly address whether 
mRNA delivered by retroviral particles is the cause of RMT, we tested whether it is 
sensitive to inhibition by shRNA as a form of an engineered restriction. We mixed 
unmodified control cells (shRNA negative) with cells coexpressing shRNA (either 
shGFP, directed against EGFP sequences on the vector mRNA, or scrambled 
shControl) and DsRed fluorescent protein as a marker from the same lentiviral 
construct. DsRed expression therefore indicates cells expressing the shRNA. We 
transduced the mixed two cell populations (shRNA negative plus shGFP and shRNA 
negative plus shControl) using RT-proficient (iRV) and RT-deficient (RMT) EGFP 
encoding vectors and analyzed them 36 h posttransduction. shRNA directed against 
EGFP specifically and significantly (P<0.0001; n=9) inhibited the RMT-mediated 
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expression of this protein, whereas the expression of the scrambled control shRNA 
had no effect (Fig. 3).  
 
        
 
In contrast, the transduction efficiency of iRV particles was not significantly altered by 
shRNAs targeting the retroviral RNA genome, although we found a clear reduction of 
de novo synthesized RNA in cells transduced with iRV (Fig. 3A, lower dot blot of iRV, 
compare upper right quadrant showing cells expressing the shRNA and lower right 
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quadrant showing unmodified cells). The DsRed-negative, shGFP-negative cell 
population served as an internal positive control and expressed high levels of EGFP 
after transduction. The degrees of shRNA-mediated inhibition of EGFP expression 
were similar for RMT and integrating vectors (~2.4-fold) (Fig. 3B). Together with data 
shown in Table 1 and our previous findings (8), these data imply that retroviral 
particles can deliver unspliced retroviral RNA containing a packaging signal into 
target cells for immediate ribosomal translation.  
 
RMT is sensitive to TRIM5α  
To consider the role of the retroviral particle in RMT, we analyzed sensitivity to 
cellular restriction factors targeting the capsid protein. If RMT is mediated by 
specifically packaged mRNA contained in retroviral particles, then those formed by 
the N-tropic MLV capsid should be sensitive to restriction by huTRIM5α. To address 
this question, we packaged RT-proficient (iRV) and RT-deficient (RMT) forms of the 
Cre vector into B-tropic or N-tropic VSVg-pseudotyped MLV virions and transduced 
our previously described human (HT1080) and mouse (SC-1) Cre reporter cells (38). 
To avoid saturation of huTRIM5α restriction, retroviral supernatants were used at 
MOIs lower than 1 (MOI 0.05 to 1). In permissive murine Cre reporter cells, the 
potencies of the two virus supernatants to express Cre were comparable (Fig. 4A). 
However, when transducing human Cre reporter cells (which endogenously express 
huTRIM5α), the N-tropic vector particles were strongly restricted, independently of 
their ability to reverse transcribe. Both N-tropic vector particles were inhibited by 
huTRIM5α. SF91aPBS.nlsCre (RMT) was inhibited by around fourfold (Fig. 4D and 
E) and SF91.nlsCre (which can initiate RT and form integrating retroviral DNA) by 
around 10-fold compared to the inhibition of their B-tropic counterparts (Fig. 4C and 
E). Figure 4F shows the potencies (Cre activity in mouse Cre reporter cells) of all 
retroviral supernatants used for the experiments whose results are illustrated in Fig. 
4C to E. Together, these experiments reveal that RMT is sensitive to restriction by 
huTRIM5α and that the restriction occurs independently of RT.  
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We next addressed whether the restriction by huTRIM5α can be overcome by 
treatment with the proteasome inhibitor MG132. Since MG132 increases the 
efficiency of lentiviral infection in a cell-type dependent manner (27), we examined 
the influence of MG132 on restricted particles in comparison to its influence on non-
restricted particles. To minimize unspecific toxicity, we used MG132 at a relatively 
low concentration (0.5 µmol/liter), which is at least four times lower than the 
concentration used in related studies on retroviral restriction (5, 29). Both the RT-
proficient (iRV) (Fig. 4C and E) and RT-deficient (RMT) (Fig. 4D and E) N-tropic 
vector particles were partially rescued by MG132. Rescue occurred at all doses of 
virus tested, revealing that the doses used did not result in a saturation of either 
restriction or proteasomal degradation. Importantly, treatment with MG132 
significantly increased the efficiency of Cre delivery by N-tropic particles, with similar 
values for RT-proficient and RT-deficient particles (4.8-fold and 4.5-fold, respectively) 
(Fig. 4E). This increase of infectivity mediated by MG132 was greater in the context 
of restricted particles (P<0.001; n=12) (Fig. 4E). MG132 only lead to a slight increase 
in the infectivity of unrestricted RT-deficient particles (1.5-fold), whereas it even 
reduced the infectivity of RT-proficient particles, possibly due to a residual cytotoxic 
effect. Nevertheless, proteasome inhibition did not allow a complete rescue of RMT 
following restriction by huTRIM5α. 
 
The restriction factor Fv1 also inhibits RMT 
Previous work has demonstrated that restriction by the mouse gag-like restriction 
factor Fv1 occurs after RT (13). However, Fv1 can compete with TRIM5α for 
restricted virus, suggesting that it interacts with the virion at the same time as 
TRIM5α, before significant RT has occurred (21). To address whether restriction by 
Fv1 depends upon initiation of RT, we packaged RT-proficient (iRV) and RT-deficient 
(RMT) Cre vectors with the B-tropic gag-pol and transduced human Cre-reporter cells 
that were engineered to express Fv1n. Interestingly, Fv1n clearly reduced RMT 
(mediated by SF91aPBS.nlsCre), although this restriction was less profound than 
that observed with the RT-proficient vector (SF91.nlsCre) (Fig. 5). We thus found that 
Fv1n partially inhibits RMT, a process which, as shown above, requires all retroviral 
proteins except reverse transcriptase and integrase. This reveals that restriction by 
Fv1n occurs irrespective of the initiation of RT, the formation of retroviral DNA and the 
subsequent maturation of the PIC.  
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Restriction by TRIM5α, but not Fv1, is associated with reduced retroviral 
genomic RNA levels 
Since RMT is mediated by packaged retroviral genomic RNA (Table 1; Fig. 3) and is 
restricted by TRIM5α (Fig. 4) and, to a lesser extent, by Fv1n (Fig. 5), we wanted to 
know whether the restriction is associated with destruction of the retroviral genomic 
mRNA. To address this point, we transduced human Cre reporter cells endogenously 
expressing huTRIM5α with restricted (N-tropic) or nonrestricted (B-tropic) RMT 
particles, in the presence or absence of MG132. At 2, 4, 6 and 8 h postinfection, we 
harvested total RNA and performed quantitative real-time RT-PCR using primers 
targeting the retroviral genomic RNA. Real-time PCR analysis revealed that the 
restriction by TRIM5α was associated with the degradation of the retroviral genomic 
mRNA (Fig. 6A). Strikingly, 8 h posttransduction, the RNA levels of the restricted N-
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tropic particles were 10.8 times lower than for the nonrestricted B-tropic particles. In 
contrast, we found no significant difference for N- and B-tropic particles in 
nonrestrictive mouse Cre reporter cells (data not shown). Interestingly, proteasome 
inhibition with MG132 allowed partial recovery of the retroviral genomic RNA (4.5-
fold), suggesting that it is lost through recruitment to the proteasome by TRIM5α (Fig. 
6A). The reduction of mRNA was predominantly detectable at the later time point 
(>2h), suggesting that degradation does not immediately follow particle uptake. 
Furthermore, we monitored, in the same cell populations, the fate of the retroviral 
capsid (p30) in restrictive and nonrestrictive cells (Fig. 6C) up to 8 h after trans-
duction. Similar to the RNA data, we saw reduced capsid levels for the restricted N-
tropic particles, which could be compensated by addition of MG132.  
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Restriction by Fv1n did not alter the levels of retroviral genomic RNA (Fig. 6B). This is 
consistent with the observation that Fv1-restricted particles can still undergo RT but 
are blocked at a later step (13). Together, the results of these experiments reveal 
that RMT is mediated by retroviral particles and is thus dependent on the amount of 
mRNA made accessible to ribosomes in the target cells. Furthermore, these 
observations support the notion that Fv1 and TRIM5α interact with the particle 
independently of initiation of RT and that restriction by TRIM5α leads possibly to 
proteasomal degradation of the particle. 
 
d. Discussion 
Our experiments have established that RT-deficient retroviral particles are able to 
make their genome accessible for translation in the unspliced gag-pol reading frame. 
Retroviruses are thus capable of RMT, resulting in low-level, transient expression of 
virally encoded gene products in transduced cells. RMT may occur if retroviral 
particles have not packaged a tRNA primer, if reverse transcriptase is mutated, or, as 
used in our experimental approach, if retroviral vectors are generated that are unable 
to bind the tRNA primer. Previously, we have demonstrated that retroviral RMT 
depends upon the presence of the packaging motif in the transduced mRNA, gag, 
and env, but not reverse transcriptase. The passive transfer of protein and the 
contamination of retrovirus-conditioned medium with plasmid DNA have been ex-
cluded as underlying this phenomenon (8). Here, we have demonstrated that the 
efficiency of RMT correlates with the expression of packaged retroviral mRNA rather 
than the amount of protein encoded in the gag-pol reading frame in viral producer 
cells (Table 1). Finally, the sensitivity to shRNA expressed in target cells (Fig. 3) 
clearly shows that the viral mRNA is responsible for RMT. 
We went on to show that RMT is restricted by cytoplasmic restriction factors TRIM5α 
and Fv1, both of which are directed against the retroviral capsid. The side-by-side 
comparison of RT-deficient (i.e., RMT) with RT-competent integrating virus (iRV) 
reveals that TRIM5α restricts RMT particles to a lesser extent than iRV. This implies 
that RMT-competent virions are partially able to escape restriction and release their 
nucleic acids for translation. In other words, we hypothesize that the somewhat 
weaker restriction of RMT particles than of iRV particles by restriction factors 
targeting the capsid reflects the fact that iRV particles still have to complete a number 
of complicated steps in their life cycle (RT, formation of a PIC, and integration), 
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whereas RMT particles only have to release their mRNA for subsequent translation. 
Importantly, data obtained in functional assays of biological activity mediated by RMT 
correlated well with RNA levels determined by real-time PCR.  
Furthermore, restriction of RMT particles could be rescued more efficiently than 
restriction of RT-proficient particles by inhibition of the proteasome with MG132, 
suggesting that the restriction of RMT is more dependent on the proteasome. The 
RNA data correlated with the capsid levels determined by Western blot analysis (Fig. 
6).  
We also found that RMT is sensitive to restriction by Fv1 when delivered by the 
appropriately Fv1 sensitive capsid. Again, RMT vectors were less sensitive to this 
form of restriction than reverse-transcribing vectors. Strikingly, we found that restric-
tion by TRIM5α, but not by Fv1, leads to clear destruction of the viral RNA (Fig. 6). 
These data are consistent with recent observations that inhibition of the proteasome 
during restriction by TRIM5α rescues RT and support the notion that the RT block is 
due to destruction of the particle, and the RNA by the proteasome (1, 39). While the 
proteasome might not degrade the RNA directly, we imagine that degradation of the 
virion protein would render the genome sensitive to degradation by cellular 
nucleases. These observations are inconsistent with an uncoating mechanism for 
TRIM5α, which might be expected to increase the release of the genome and RMT 
(5, 22, 23). Finally, our use of retroviral vectors which cannot reverse transcribe due 
to modification of the PBS demonstrates that sensitivity to TRIM5α and proteasomal 
degradation of the mRNA do not depend on initiation of RT.  
In summary, RMT suggests a potential evolutionary role of immediate early 
translation of retroviral nucleic acids. As shown here, this by-product of the retroviral 
life cycle can be exploited to study cytoplasmic restriction of retroviral particles, using 
both biological activity and biochemical parameters as readouts. We thus found that 
the sensitivity to TRIM5α does not depend on the initiation of RT and that 
degradation of RNA and capsid is correlated with restriction mediated by TRIM5α. 
Our data also support a hypothesis that, in nonrestrictive cells, retroviral nucleic acids 
become accessible to host factors, including ribosomes, as a result of particle 
remodeling during cytoplasmic trafficking. Particle modifications that trigger mRNA 
release after entry are thus expected to further increase the efficiency of RMT. 
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e. Materials and Methods 
Retroviral vectors and plasmids 
Gammaretroviral vectors termed SF91 were derived from SF91.GFP (11, 31). The 
vector SF91aPBS.GFP.pre was generated by introducing the artificial PBS as an 
XbaI/ApaI fragment from SF91aPBS.GFP (8, 15) in SF91.GFP.pre (31). The 
retroviral vector used for engineering human Cre reporter cells to express Fv1n was 
derived from pCFCR (21). The red fluorescent protein of this construct was first 
excised by AgeI and NotI, and the Zeocin resistance gene inserted as a blunt 
NcoI/SalI fragment from pT/Zeo (kindly provided by Z. Ivics, Max-Delbrück-Center, 
Berlin, Germany). 
The basic lentiviral construct pRRL.PPT.SF.GFPpre has been previously described 
(30) and is a derivative of pRRL.PPT.PGK.GFPpre (kindly provided by L. Naldini, 
Milano, Italy). For the construction of a lentiviral shRNA construct, an shRNA 
cassette consisting of an H1 (Pol. III) promoter and an shRNA coding sequence 
directed against EGFP were introduced into the 3’ dU3 region using a previously 
introduced unique SnaBI site. The shRNA sequence was created using primer 5’ 
GFP (5’-GATCCCCGCGGCAAGCTGACCCTGAAGTTCATTTCAAGAGAATGAACTT 
CAGGGTCAGCTTGCCGTTTTTGGAAA-3’) and 3’ GFP (5’-AGCTTTTCCAAAAACG 
GCAAGCTGACCCTGAAGTTCATTCTCTTGAAATGAACTTCAGGGTCAGCTTGCC
GCGGG-3’), self-annealed and cloned as a BglII/HindIII fragment into pSuper 
(Oligoengine, Seattle, WA, USA). From there, the H1 promoter plus shRNA were 
cloned as a SmaI/HincII fragment into the SnaBI site of the lentiviral vector (see 
above). 
To create integration-defective lentiviral vectors, an integrase-deficient gag-pol 
construct (pcDNA3.gpD64V.4xCTE) harboring a D64V point mutation in integrase 
was used (kindly provided by M. Milsom, Cincinnati Children’s Research Foundation, 
Cincinnati, OH).  
 
Gammaretroviral and lentiviral particle production 
Gammaretroviral and lentiviral vector supernatants were produced in human 293T 
packaging cells using the calcium phosphate precipitation method (Calcium 
phosphate transfection kit, Sigma Aldrich, Munich, Germany), assisted by 25 µM 
chloroquine (Sigma Aldrich). The day before transfection, 5 x 106 293T cells were 
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seeded in a 10-cm dish. For gammaretrovirus production, the retroviral vector 
expression plasmid (5 µg) was cotransfected with expression plasmids for Moloney-
MLV gag-pol (M57DAW, 15 µg) and either ecotropic (K73, 3 µg; kindly provided by T. 
Kitamura, Tokio, Japan) or VSVg (pMD.G, 2 µg) envelope. For the production of N- 
or B-tropic gammaretroviral particles, we used 5 µg of either pCIG3N or pCIG3B gag-
pol expression plasmids (4). To ensure equal transfection efficiencies of 
gammaretroviral nlsCre vectors, 1 µg of the pEGFP-C1 expression plasmid (BD 
Clontech, Heidelberg, Germany) was cotransfected. For lentivirus particle production, 
5 µg of the lentiviral vector expression plasmids were cotransfected with 12 µg 
lentiviral gag-pol (pcDNA3.gp.4xCTE), 5 µg Rev (RSV-Rev kindly provided by T. 
Hope, Chicago, Northwestern University, IL, USA) and 2 µg VSVg envelope 
expression plasmids. Supernatants were harvested 36 h, 48 h, and 60 h post- 
transfection, filtered through a 0.22-µm filter (Millipore, Schwalbach, Germany), and 
stored at -80°C until use. For comparison of RMT pa rticles with episomal lentiviral 
particles (Fig. 1), supernatants were concentrated via ultracentrifugation as 
previously described (30). 
 
Cell culture and transduction 
293T, SC-1, HT1080, and previously described human (HT1080 derived) and mouse 
(SC-1 derived) Cre reporter cells (8, 38) were grown in Dulbecco´s modified Eagle´s 
medium (Biochrom, Berlin, Germany) supplemented with 10% fetal calf serum. 
Human Cre reporter cells ectopically expressing Fv1n were cultured in the presence 
of 150 µg/ml Zeocin (Invitrogen, Karlsruhe, Germany). The day before transduction, 5 
x 104 cells were seeded. Serial dilutions of retroviral or lentiviral supernatants were 
applied to the cells either in the presence or in the absence of 0.5 µM MG132 (Cal-
biochem, Bad Soden, Germany). The transduction procedure was assisted by prot-
amine sulfate (4 µg/ml, Sigma Aldrich) and centrifugation for 60 min at 400 x g and 
32°C. After 14 h of incubation, the virus-containin g medium was replaced with fresh 
medium. The percentage of EGFP-positive or recombined cells was determined by 
flow cytometry (fluorescence-activated cell sorting [FACS]) analysis at the indicated 
time points. 
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Western blotting 
Human or mouse Cre reporter cells were infected with B- or N-tropic nlsCre-encoding 
RMT particles (MOI of 1) either in the presence or absence of 0.5 µM MG132 
(Calbiochem). Ninety minutes posttransduction, the supernatant-containing medium 
was removed, the cells were washed three times with phosphate-buffered saline, and 
fresh medium either with or without MG132 was added. At the indicated time points, 
cells were harvested and cell lysates prepared using proteinase inhibitors (Complete 
Mini, Roche, Mannheim, Germany) containing radioimmunoprecipitation assay buffer. 
Samples were separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (12.5%), transferred to nitrocellulose membranes (Bio-Rad, Munich, 
Germany), and probed with goat anti-RLV p30 serum (final concentration, 2 µg/ml, 
kindly provided by S. K. Ruscetti, National Cancer Institute at Frederick [NCI-
Frederick], Frederick, MD) in Tris-buffered saline with 0.05% Tween and 3% milk 
powder (TBST-3% dry milk). A donkey anti-goat horseradish peroxidase conjugate 
(Santa-Cruz, Heidelberg, Germany) diluted 1:2,000 in TBST/3% dry milk served as 
the secondary antibody. Detection was carried out by chemiluminescence (ECL, 
Pierce, Bonn, Germany). For the detection of Erk protein, membranes were 
incubated with polyclonal rabbit anti-Erk-2 (1:2,000 in TBST/3% dry milk; Santa-
Cruz), followed by incubation with goat anti-rabbit horseradish peroxidase (Santa-
Cruz) diluted 1:2,000 in TBST/3% dry milk.  
 
Real-time RT-PCR quantification 
On the day of transduction, 3 x 106 murine or human Cre reporter cells or human 
Cre-reporter cells ectopically expressing Fv1n were infected by B- or N-tropic nlsCre-
encoding retroviral particles (supernatants were adjusted to Cre activity determined 
on permissive cells) either in the presence or absence of 0.5 µM MG132 
(Calbiochem). At 2, 4, 6 and 8 h posttransduction, cells were washed three times with 
phosphate-buffered saline and harvested, and their total RNA was prepared using 
the RNAzol extraction method (WAK Chemicals, Steinbach Germany). Before RT-
PCR, RNA samples were treated two times with RNase-free TURBO DNase 
(Ambion, Dresden, Germany) and purified (Qiagen RNeasy Mini Kit) according to the 
manufacturer´s protocol (Qiagen, Hilden, Germany). First-strand cDNA synthesis was 
performed with Quanti-Tect RT Kit (Qiagen) using Oligo(dT) and random hexamer 
primers (MBI Fermentas, St.-Leon-Rot, Germany) in the same molecular ratio. 
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Quantitative PCR was performed with an Applied Biosystems 7300 Real-Time PCR 
system (Foster City, CA, USA) using a Quanti-Tect SYBR Green Kit (Qiagen). The 
amplification of the Cre DNA sequence was carried out by using oligonucleotides 5`-
AACATTTGGGCCAGCTAAACA-3´ and 5´-AGAGCCTGTTTTGCACGTTCA-3´. The 
Cre-specific signal was normalized to the signal obtained by the amplification of 
mouse or human β-actin DNA with oligonucleotides 5`-CCTCCCTGGAGAAGAGCT-
A-3´ and 5´-TCCATGCCCAGGAAGGAAG-3´. Results were quantified using the 
comparative threshold cycle method. 
 
Characterization of RMT vector and wild-type retroviral supernatants 
Retroviral SF91.nlsCre and SF91aPBS.nlsCre supernatants were produced, har-
vested and concentrated via ultracentrifugation (32). The obtained retrovirus pellets 
were resuspended in phosphate-buffered saline, aliquotted, and stored at -80ºC. For 
determination of the RNA content, concentrated supernatants were pretreated with 
RNase-free TURBO DNase (Ambion). Retroviral RNA was extracted with an RNeasy 
Micro Kit (Qiagen) according to the manufacturer´s protocol, including an additional 
DNAse treatment. First-strand cDNA synthesis and real-time PCR quantification were 
performed as described above. An in vitro-transcribed retroviral RNA derived from 
SF91.nlsCre served as the standard for the quantification of RNA. All samples were 
checked for plasmid DNA contamination. Western blot analysis for retroviral CA (p30) 
was performed as described above using denatured supernatants. The levels of 
reverse transcriptase activity of retroviral supernatants were determined using a 
RetroSys C-type RT activity kit (Innovagen, Lund, Sweden) according to manufactur-
er’s instructions.  
 
Statistical analysis 
Data from the experiments are expressed as mean ± standard deviations. Student´s 
paired t test was used for the comparison of differences between indicated groups. A 
P<0.05 was considered significant. 
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a. Abstract 
Retroviral vectors with self-inactivating (SIN) long terminal repeats not only increase 
the autonomy of the internal promoter but may also, reduce the risk of insertional 
upregulation of neighboring alleles. However, gammaretroviral as opposed to 
lentiviral packaging systems produce suboptimal SIN vector titers, a major limitation 
for their clinical use. Northern blot data revealed that low SIN titers were associated 
with abundant transcription of internal rather than full-length transcripts in transfected 
packaging cells. When using the promoter of Rous sarcoma virus or a tetracycline-
inducible promoter to generate full-length transcripts, we obtained a strong 
enhancement in titer (up to 4 x 107 transducing units per ml of unconcentrated 
supernatant). Dual fluorescence vectors and Northern blots revealed that promoter 
competition is a rate-limiting step of SIN vector production. SIN vector stocks 
pseudotyped with RD114 envelope protein had high transduction efficiency in human 
and non-human primate cells. This study introduces a new generation of efficient 
gammaretroviral SIN vectors as a platform for further optimizations of retroviral vector 
performance. 
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b. Introduction 
Self-inactivating (SIN) retroviral vectors lack enhancer-promoter sequences in the U3 
region of their long terminal repeats (LTRs) and use internal cis-regulatory 
sequences to initiate transcription of a gene of interest.1 The SIN design has several 
important advantages: it reduces the risk of recombination to replication-competent 
retroviruses (RCR), impedes the mobilization of vector RNA in case of RCR 
superinfection, increases the autonomy of the internal promoter1 and theoretically 
reduces the risk of insertional upregulation of neighboring alleles depending on the 
choice of the internal enhancer/promoter. These features can be achieved without 
compromising the potency of the integrated transgene allele. Although the deletion of 
enhancer sequences from the LTR impairs overall transcript levels and increases 3’ 
read-through,2 improved RNA processing of the internal transcript still allows the 
generation of SIN vectors that mediate comparable transgene expression levels as 
their LTR counterparts,3 SIN vectors are thus of interest for a variety of applications 
in human gene therapy.  
On the basis of foamyvirus (FV) or lentiviruses such as the human immunodeficiency 
virus (HIV), SIN vectors can be produced from transiently transfected packaging 
cells, without substantial loss of titers compared to constructs containing intact LTR 
sequences.4,5 In contrast, the first generations of gammaretroviral SIN vectors based 
on murine leukemia virus (MLV) suffered from strongly reduced titers.1 While MLV 
vectors cannot transduce non-dividing cells, they still represent important tools for 
human gene therapy, because they do not require the incorporation of any 
sequences overlapping with coding sequences of gag, pol, env or accessory genes,6 
in contrast to the most common forms of vectors based on HIV or FV.4,5 In addition, 
MLV SIN vectors are likely to increase the safety of human gene therapy protocols 
when used under conditions where MLV-based LTR vectors already show 
therapeutic efficiency.7-10  
Before the present study, the mechanisms responsible for the severe titer reduction 
of early generations of gammaretroviral SIN vectors were unclear. When we 
introduced the post-transcriptional element (PRE) from woodchuck hepatitis virus into 
the 3’-untranslated region of SIN vectors, we were able to increase infectious titers 
above 106 transducing units per ml of unconcentrated cell-free culture 
supernatant.3,11 Owing to the mode of action of the PRE,12,13 this suggested that 
insufficient 3’ RNA processing of retroviral transcripts was partially responsible for 
  Publication 3    78   
     
reduced SIN vector yields. However, SIN titers still remained substantially reduced in 
comparison with LTR-driven counterparts, representing a potential limitation for 
clinical use. These observations suggested at least three hypotheses: (1) the 
gammaretroviral packaging signal is bipartite and involves sequences overlapping 
with the enhancer-promoter of the U3 region; (2) the interaction of the Rev-
responsive element (RRE) with Rev-protein generated in producer cells is 
responsible for the superior titer of lentiviral SIN vectors; or (3) promoter differences 
between gammaretroviral and lentiviral SIN vectors lead to a superior generation of 
full-length transcript in the lentiviral context.   
In the present study, we addressed these hypotheses by incorporating modules 
derived from state-of-the-art lentiviral vector plasmids14,15 into gammaretroviral 
constructs. As underlined by a novel dual fluorescence reporter assay, we found that 
promoter competition was the major limitation for the production of gammaretroviral 
SIN vectors. This could be overcome by using the promoter of Rous sarcoma virus 
(RSV) or a tetracycline-inducible promoter to drive expression of the full-length RNA. 
We demonstrate the potency of this new gammaretroviral design for highly efficient 
transduction of rhesus monkey CD34+ cells with SIN vectors encoding a clinically 
relevant selection marker. 
 
c. Results 
Gammaretroviral SIN vectors produce abundant internal transcripts in 
transfected packaging cells 
In previous work, we have shown that gammaretroviral SIN vectors, are as potent as 
their lentiviral counterparts in terms of transgene expression.16 Gammaretroviral SIN 
vectors, however, did not reach the same titers as their LTR-driven counterparts.3,16 
The use of the PRE from Woodchuck hepatitis virus restored SIN vector titers only 
partially.3  
To address the underlying mechanisms, we initially compared three vector 
backbones, all containing the P140K mutant of methylguanine-methyltransferase 
(MGMT; Ragg et al.17) followed by the PRE (Figure 1A). We compared our standard 
gammaretroviral LTR vector SF91,6,18 the gammaretroviral SIN vector Sin11.SF,16 
and two third-generation lentiviral vectors (Figure 1A) containing the central 
polypurine tract (cPPT).14,15 Lentiviral vectors used the internal SF promoter19 (as 
Sin11.SF) or the weaker phosphoglycerate kinase (PGK) promoter. Gammaretroviral 
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supernatants were produced in 293T cell-based Phoenix-gp packaging cells,20 and 
lentiviral vectors in 293T cells.15 All particles contained ecotropic Env proteins21,22 to 
avoid re-infection and RNA production from integrated proviruses.23 
 
 
 
The retroviral LTR vector harboring a splice-competent leader region produced both 
spliced and unspliced RNAs (Figure 1B, lane 1), the latter containing the packaging 
signal. In total RNA, a 1:1 ratio of both transcripts was reproducibly observed.3 In 
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contrast, Sin11.SF showed a predominant signal for the internal RNA produced from 
the internal promoter (Figure 1B, lane 2), in expense of the amount of genomic RNA 
available for packaging. As this correlated with the titer determined by stable transfer 
of the MGMT expression cassette into SC-1 fibroblast cells (Figure 1C), promoter 
competition was a likely explanation for the titer reduction of gammaretroviral SIN 
vectors. Surprisingly, although bearing the identical internal expression cassette, 
lentiviral vectors showed a much better ratio of genomic vs internal RNA (Figure 1B, 
lane 4). However, lentiviral titers were only slightly increased, possibly because we 
pseudotyped the particles with the ecotropic envelope (Figure 1C).  
 
Use of the RSV promoter improves the production of SIN genomic RNA 
The 5’ region of the lentiviral backbone differs from the gammaretroviral with respect 
to several features: (i) R/U5, (ii) the cPPT, (iii) the RRE, and (iv) the RSV promoter 
driving expression of the genomic RNA. We incorporated the last three modules into 
Sin11.SF encoding enhanced green fluorescent (eGFP). We found that neither the 
cPPT nor the RRE significantly influenced the ratio of genomic vs internal RNAs 
(data not shown).  
We then thus focused on modifications of the 5’ promoter driving the expression of 
full-length RNA in the packaging cells. A new set of vectors was constructed (Figure 
2A), to evaluate the extent of promoter competition with four different promoter 
configurations at the 5’ end, and three internal promoters (Figure 2A). The titer 
produced in Phoenix-gp cells is shown in Figure 2B and C provides a direct 
comparison of the RNA from packaging cells analyzed by Northern blot. In the 
Sin11.SF context, the internal SF promoter gave the highest titer in comparison to 
the promoters derived from PGK or cytomegalovirus (CMV). This suggests that a 
strong internal promoter also activates the upstream enhancer (Sin11.CMV and 
Sin11.SF in Figure 2C, lane 4). Although CMV was the strongest promoter in the 
internal position (Figure 2C), its transfer to the 5’ end (SCS vectors) did not increase 
titers (Figure 2B).  
Using the RSV promoter to drive expression of the genomic RNA (SRS vectors) 
resulted in a substantial increase in titer (Figure 2C). Depending on the internal 
promoter, titers increased up to 40-fold (Figure 2B). This correlated with an increase 
in the total amount of genomic RNA (Figure 2C, lanes 8-10).  
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In the context of the internal SF promoter, the ratio of genomic vs internal RNA 
became similar to that observed for lentiviral vectors (compare Figure 1B, lane 4 to 
Figure 2C, lane 10). Thus, lentiviral and gammaretroviral SIN vectors showed 
equivalent results when containing the upstream RSV promoter increasing the total 
amount of packageable genomic RNA.  
To further strengthen the 5’ promoter, we inserted the SV40 enhancer24,25 upstream 
of the RSV promoter (SERS series, Figure 2A). This modification further increased 
the amount of genomic RNA (Figure 2C, lanes 11-13). Titers thus reached levels of 
3-4 x 107 infectious units per ml unconcentrated cell-free supernatant (Figure 2B), 
concomitant with a further increased amount of genomic RNA (Figure 2C, lanes 11-
13). To further investigate the correlation between the amount of genomic RNA and 
the increase in titer, we quantitated the Northern blot data by phosphoimager 
analysis (Figure 2D). We observed an almost linear correlation between the amount 
of genomic RNA and the resulting titer.  
We thus reached the maximum titer that we achieved with LTR-driven vectors under 
our packaging conditions, indicating that even higher titers might be achievable when 
improving other components of the packaging systems. Of note, the vector 
modifications used to increase the retroviral titer leave the sequence of the integrated 
provirus unchanged. 
We then lowered the amount of transfer vector from 2 µg to 0.5 µg, revealing greater 
differences in titer upon modification of the 5’ end (Figure 2E). The upstream RSV 
promoter led to 10-fold enhancement in titer when the amount of transfer vector was 
limiting and only to a 2.5-fold increase when the transfer vector was provided in 
excess (Figure 2E). Furthermore, the threshold at which the amount of genomic RNA 
becomes limiting was reached with the SRS vectors at 0.5 µg, in contrast to the 
conventional SIN vectors (5 µg of transfer vector; Figure 2E and data not shown).   
In addition, the use of the RSV promoter also showed beneficial effect in the LTR 
context as shown by retroviral pseudotransduction26 (Supplementary Figure 1) and 
by integration-competent LTR vectors encoding eGFP, which showed a 3-fold titer 
increase (data not shown). 
 
Performance of the new SIN vectors in primary hematopoietic cells 
Using the SRS backbones, we designed efficient vectors expressing the clinically 
relevant selection marker MGMT transgene (Figure 3).16 The substitution of the 
  Publication 3    83   
     
MPSV (SIN vectors) for the RSV promoter (SRS vectors) led to a 3-fold relative 
increase in vector titers (determined on HT1080 cells, data now shown).  
In order to test the performance of the vector supernatants on primary cells, we 
transduced rhesus CD34+ cells with RD114/TR pseudotypes using multiplicities of 
infection (MOIs) of 1, 5 and 10 (Figure 3). Using an MOI of 10, productive 
transduction of more than 90% of Rhesus CD34+ cells was obtained (Figure 3, one 
representative experiment is shown). Furthermore, we transduced human CD34+ 
cells with MGMT encoding vectors at an MOI of 1 resulting in 43% MGMT expressing 
human hematopoietic cells (data not shown).  
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A dual fluorescent vector system suggests a Pol II occupation model for 
promoter competition  
To address the mechanism of promoter competition, we developed a dual fluorescent 
vector by introducing the cDNA for the Discosoma red fluorescent protein Express 
(DsRed)27 upstream of the internal promoter driving eGFP (Figure 4A). The amount 
of DsRed should correlate with the amount of genomic RNA, and eGFP should mirror 
the quantity of the internal RNA. Both fluorescent proteins allow fast and quantitative 
analysis in single cells owing to similar maturation kinetics (Clontechniques XVII: 3, 
2002) as opposed to the Northern analysis that reflects the average RNA production 
in a cell population.  
We started by comparing the basic retroviral SIN vectors with the RSV-modified 
vectors harboring two different internal promoters. Figure 4B shows a representative 
fluorescence-activated cell sorter (FACS) analysis of transfected Phoenix-gp cells. 
Standard SIN vectors showed an unfavorable ratio of green (internal RNA) vs red 
fluorescence (genomic transcript), as expressed by the quotient of the y vs x mean 
fluorescence intensity (Figure 4B, upper left panel). In contrast, the RSV modification 
increased this ratio six-fold; the dot plot analyses revealed that the effect of the RSV 
promoter was independent of the expression level (Figure 4B, upper right panel). 
These data are in line with titer determinations (Figure 4C) and RNA levels (Northern 
blot in Figure 4D, compare lanes 2, 3 to 6, 7). We observed a direct correlation 
between the amount of genomic RNA and increase in titer. However, for the SRS 
constructs, the amount of genomic RNA increased in case of the internal CMV 
promoter, but it led only to minor titer increase, probably because in this setting 
saturating levels were already reached (Figure 4D and C, lanes 6 and 7). 
We next used the dual fluorescence vectors to study the mechanisms of promoter 
competition. The downstream promoter might be occupied by read-through trans-
cription of the RNA polymerase II (pol II) transcription complex originating at the 
upstream promoter.28,29 Besides, epigenetic promoter modifications could occur, 
which are probably more important following transgene integration.30-32 If promoter 
occupation by RNA polymerase II is the relevant mechanism, inserting a 
transcriptional termination signal (polyA signal) 5’ of the internal promoter should 
rescue its activity by reducing the probability of transcriptional read-through.33 We 
thus cloned the bovine growth hormone (BGH) polyA in front of the internal promoter 
resulting in pSRS.Red.pA.SF or pSRS.Red.pA.CMV (Figure 4A). FACS analysis of 
the parental vectors confirmed our previous findings (Figure 4B, lower left panel).  
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The presence of the BGH polyA increased the eGFP signal (reflecting the internal 
transcript) as expressed by the ratio of mean fluorescence intensities (Figure 4B, 
lower right panel). The BGH polyA reduced vector titers strongly (Figure 4C and D), 
but not completely; this suggested that residual polymerase read-through did occur, 
especially when transcripts were driven by the RSV promoter (Figure 4D).  
Taken together, these studies reveal promoter competition in SIN vector plasmids as 
a mechanism that potentially reduces the yield of genomic RNA. This can be 
overcome by the choice of a suitable 5’ enhancer/promoter. 
 
Tetracycline-inducible promoters also drive high levels of genomic vector 
transcripts for high titer SIN vector production 
Tetracycline-inducible promoters (Tet) in combination with the respective trans-
activators (TAs) are very potent promoter/enhancer combinations that mediate high 
and robust expression.34 Tet-inducible promoters have already been successfully 
used in the LTRs of lentiviral vectors to create all-in-one vectors with tet-promoter 
and TA35,36 and to drive the genomic RNA of lentiviral vectors in inducible packaging 
cells.37 Therefore, it was tempting to test whether a Tet-inducible promoter in-
corporated into the retroviral 5’ LTR (Figure 5A) is also capable of generating 
sufficient titers comparable to the SERS vector series (Figure 2). Potentially, this 
would allow the stable production of vectors with transgenes whose over-expression 
is toxic for producer cells. Furthermore, high titer virus production would be possible 
in cell lines where the RSV promoter is not active enough (in light of promoter 
competition). Figure 5B shows the results of a representative experiment. The Tet-
inducible SIN vector Tet11.SF was transfected with or without the transactivator (TA) 
and set into comparison with the SERS11.SF vector (without TA). Titers of the Tet-
inducible vector reached almost 2 x 107 transducing units per ml supernatant. Figure 
5C shows the corresponding Northern blot of the packaging cell line. Interestingly, 
the amount of internal transcript also increased implying an interaction between the 
5’ and the internal promoter. The combination of the RSV promoter and SV40 
enhancer still produced more genomic RNA (Figure 5C, lane 4), but this did not 
translate into titer, probably because gag/pol or env were limiting (experiment 
conducted with saturating plasmid amounts) (Figure 2D). In summary, this indicates 
that Tet-inducible promoters are useful for high-titer production of gammaretroviral 
SIN vectors. 
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d. Discussion 
The present study was undertaken to overcome a major limitation of gammaretroviral 
SIN vectors, which is the loss of titer observed upon deletion of the 3’ U3 region. 
Theoretically, all classes of SIN vectors are faced with the problem that a non-
specific internal promoter will be active in the packaging cells and generate RNAs 
that do not contribute to the titer but rather reduce the amount of genomic RNA. 
However, the use of a strong internal promoter is often desirable in the target cell to 
reach a therapeutic threshold, as for the expression of metabolic selection markers,38 
genes antagonizing viral infections39 or recombinant T-cell receptors.40 
Our data obtained upon transient transfection in packaging cells revealed that 
insufficient production of full-length transcript from the 5’ promoter is a major 
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limitation of gammaretroviral SIN vectors. As we found that currently used lentiviral 
vectors produced greater amounts of genomic RNA, we screened through different 
modules present in the lentiviral backbone (RRE, cPPT, 5’ promoter). Interestingly, 
neither the RRE nor the cPPT were able to produce higher titers in the 
gammaretroviral background, not even in the presence of Rev (data not shown).  
We rather find that high production of genomic RNA mainly depends on the choice of 
the 5’ promoter. Both RSV and tetracycline-inducible promoters led to high SIN 
vector titers. Why these promoters lead mediate production of genomic RNA might 
be explained by studies with lentiviral vectors. One aim during construction of third- 
generation lentiviral vectors was to become Tat-independent during the production 
process.15 The RSV promoter was found to perform this function in the so-called third 
generation lentiviral vectors and to be superior to CMV15 as in our context (Figure 2). 
Also, Kafri et al. successfully generated lentiviral SIN vectors using a tetracycline-
inducible promoter to drive the genomic transcript.35 Our data obtained in the context 
of gammaretroviral vectors, which are Tat-independent a priori, implies that recruiting 
an elongation competent pol II complex like the Tat-dependent HIV LTR and not only 
the basal promoter strength is important to overrule the internal promoter. 
Accordingly, use of the even “stronger” CMV promoter to drive genomic retroviral 
RNA expression did not give rise to higher titers.  
If the elongation rate of RNA pol II is important, the density of transcriptionally 
engaged polymerases on the internal promoter suppresses its activity.28,41,42 
Accordingly, we found that an efficient cellular termination signal placed upstream of 
the internal promoter activated the internal promoter, although residual read-through 
over the cellular polyA signal was still observed. Secondly, we enhanced 
transcriptional elongation by adding the 72 bp enhancer repeats from SV40 upstream 
of the RSV promoter,24,43 which further increased the amount of genomic RNA and 
vector titers.  
Competition between neighboring promoters could also occur at the level of 
enhancer interactions, with the stronger promoter attracting the enhancers of its 
neighbor. This might explain why the strong internal SFFV enhancer-promoter led to 
a higher SIN titer than the internal PGK promoter being the weakest of the promoters 
tested.17 However, the SV40 enhancer modification together with the usage of the 
RSV promoter makes the vectors less dependent on interactions with the internal 
promoter (Figure 2C). 
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We conclude that promoter competition is a major hindrance for the production of 
gammaretroviral SIN vectors and that both enhancer competition and promoter 
occupation need to be addressed when attempting to improve SIN vector titers. 
Increasing the processivity of the 5’ promoter enhanced vector titers by up to 40-fold, 
dependent on the cDNAs and internal promoters used. This enables the production 
of high titer supernatants using relatively low amounts of transfected plasmid, as 
required for efficient clinical-scale gene transfer. For a clinical study that explores the 
feasibility and safety of gene transfer into hematopoietic cells in adult patients, 
roughly 2 x 109 infectious particles would be required (5 x 106 CD34+ cells/kg, 70 kg 
body weight, two transductions with three infectious units per cell). When 
pseudotyping SRS and SERS vectors with human-infectious envelopes GALV and 
RD114, we reproducibly obtained titers of 1 x 107 infectious units per ml of 
unconcentrated cell culture supernatant (data not shown). Two hundred milliliters 
supernatant would thus be sufficient for the treatment of a single patient, and 2.4 
liters for an entire phase I clinical trial including preclinical safety tests. Because 106 
packaging cells yield about 1 ml supernatant per harvest, and at least three high titer 
harvests can be obtained following transient transfection, not more than 8 x 108 
packaging cells would have to be transfected to obtain sufficient material for a phase 
I study. As 0.5 µg of SERS plasmid suffices for high titer transient production from 5 x 
106 packaging cells (Figure 2E), less than 100 µg plasmid DNA would be required for 
clinical-grade vector production. This reduces the costs of GMP-grade plasmid 
production and lowers the risk of plasmid contamination of retroviral supernatants. 
Based on a better understanding of other limiting components of the vector pro-
duction system, further improvements will likely be possible.  
 
e. Materials and Methods 
Plasmids 
MGMT-encoding gammaretroviral vectors (pSF91, pSin11.SF) and lentiviral vectors 
(pRRL.PPT.PGK and pRRL.PPT.SF) have been previously described.16 In brief, 
pSF91 encodes an LTR-driven vector,6,18 and pSin11.SF a corresponding SIN vector 
using the same SFFVp U3 region (SF; including the enhancer; -342 to +18, relative 
to the transcriptional start site, GenBank no. AJ224005) as an internal promoter. 
pRRL.PPT.PGK and pRRL.PPT.SF are lentiviral SIN vectors with internal promoters 
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human PGK and SF, respectively. The basic lentiviral construct pRRL.PPT.PGK. 
eGFP.PRE was kindly provided by Luigi Naldini (Milano, Italy).  
For a functional comparison of different promoters in the 5’ LTR, we constructed a 
modular vector set using 4 different promoters in the 5’ LTR in relation to three 
different internal promoters. As internal promoters we used CMV, PGK (GenBank no. 
M11958, nt. 5-516) or SF. The 4 versions of the 5’ LTR were as follows: 
Our former SIN series uses the MPSV U3 region to transcribe the full-length RNA in 
transfected packaging cells.3 The SCS series represents SIN vectors containing the 
CMV promoter fused to the start site (+1) of the full-length RNA. SRS constructs are 
SIN vectors that use the RSV U3 fused to the start site of the full-length RNA. The 
SERS series consists of SIN vectors that use a combination of the SV40 en-
hancer24,25 and the RSV U3 fused to the start site of the full-length RNA.  
Modified 5’ LTRs were cloned by overlap-polymerase chain reaction (PCRs). For the 
amplification of the CMV promoter (GenBank no. K03104, nt. -582 to -1, relative to 
transcriptional start site), primers 5’CMVafl (5’-CGATCTTAAGTAGTTATTAATAGT 
AATCAA-3’) and 3’CMVR (5’-GTCAATCGGAGGACTGGCGCCGGTTCACTAAACCA 
GCTCTG-3’), 5’CMVR (5’-CAGAGCTGGTTTAGTGAACCGGCGCCAGTCCTCCGAT 
TGAC-3’) and 3’Leaderbgl (5’-CCAGATACAGATCTAGTTAGCCAA-3’) were used. 
PCR templates were pcDNA3 (Invitrogen, Karlsruhe, Germany) and pSF91,6 
respectively. The PCR fragment was cloned into pSin11SF using AflII and BglII sites. 
For amplification of the RSV promoter (GenBank no. J02342, nt. -233 to -1, relative 
to transcriptional start site) primers 5’RSVscaafl (5’-GCTTAGTACTCTAGCTTA 
AGAATGTAGTCTTATGCAATACT-3’) and 3’RSVRoverlap (5’-AGTCAATCGGAGGA 
CTGGCGCGTTTATTGTATCGAGCTAGGC-3’), 5’RSVRoverlap (5’-GCCTAGCTCG 
ATACAATAAACGCGCCAGTCCTCCGATTGACT-3’) and 3’LeaderBgl (see above) 
were used. Templates for this overlap-PCR were pRSV-Rev (kindly provided by Tom 
Hope, Chicago, IL, USA) and pSF91, respectively. The PCR-fragment was cloned 
into the pSin11.SF using AflII and BglII restriction sites. The SV40 enhancer 
(GenBank no. AF025845, nt. 18-252), which includes two 72 bp tandem repeats was 
amplified using primers 5’SV40enh (5’-CTACTTAAGACGCGTGGCCTGAAATAAC 
CTCTGAA-3’) and 3’SV40enh (5’-GCTACTTAAGGGACTATGGTTGCTGACTA-3’) 
and the pRL-SV40 plasmid (Promega, Mannheim, Germany) as a template. The PCR 
product was transferred into the AflII site of pSRS11.SF (upstream of the RSV 
promoter). To clone a tetracycline-inducible promoter into the 5’ LTR to drive the full 
length vector RNA, we amplified the promoter fragment via PCR using primers 
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5’Tet11afl (5’-GCTACTTAAGCTTCTTTCACTTTTCTCTGTCA-3’) and 3’Rkpn (5’-
GAGAACACGGGTACCCGGGC-3’) and plasmid ptES1-1(g)p. The tetracycline-
inducible promoter consists of a tet-operator hexamer with 4C specificity fused to the 
Moloney murine leukemia virus (MMLV) minimal promoter. The resulting PCR 
fragment was cloned into the AflII and KpnI sites of the 5’ LTR of pSRS11.SF. All 
PCR fragments were confirmed by sequencing.  
To insert the DsRed Express (Clontech, Mountain View, CA,USA) cDNA and the 
BGH polyadenylation signal (polyA) downstream of the packaging signal and 
upstream of the internal promoter, a new multiple cloning site (MCS) was 
constructed, in which successively the DsRed Express sequence and the BGH polyA 
were included. The phosphorylated oligonucleotides 5’leaderMCS (5’-GCTGACGCG 
TACTAGCGCTGACTTCGAAGC-3’) and 3’leaderMCS (5’-GGCCGCTTCGAAGTCA 
GCGCTAGTACGCGTCAGCTGCA-3’) were annealed and ligated into the PstI/NotI 
opened sites of the retroviral leader region of pMP71-CD34-2A-eGFP to introduce 
AflII, Eco47III and BstBI restriction sites. The DsRed Express cDNA (Clontech) was 
PCR-amplified with primers 5’DsRedmlu (5’-GCCTACGCGTGTCGCCACCATGGCC 
TCCTCCGA-3’) and 3’DsRedeco47III (5’-GTCTAGCGCTCTACAGGAACAGGTGG 
TGGC-3’) and cloned into the respective sites of the leader MCS. The BGH polyA 
(232 bp, template pcDNA3, Invitrogen) was amplified via PCR with primers 
5’BGHpolyAcla (5’-GCTAATCGATACTGTGCCTTCTAGTTGCCA-3’) and 3’ BGH 
polyAsal (5’-GCATGTCGACCATAGAGCCCACCGCATC-3’), digested with SalI and 
ClaI, treated with Klenow polymerase and ligated into the Eco47III opened leader 
MCS.  
 
Cell lines, transfections and transductions 
Phoenix-gp packaging cells (kindly provided by G. Nolan, Stanford, CA, USA) and 
293T cells were used for retroviral and lentiviral supernatant production, respectively. 
Phoenix-gp, 293T, HT1080 and murine fibroblast SC-1 cells were maintained in 
Dulbecco’s modified Eagles medium (DMEM, Gibco, Gaithersburg, MD, USA) 
supplemented with 10% FCS, 100 U/ml penicillin/ streptomycin, and 2 mM glutamine. 
The day before transfection, 5 x 106 Phoenix-gp or 293T cells were plated on a 10 
cm dish. The medium was exchanged and 25 µM chloroquine (Sigma-Aldrich, 
Munich, Germany) was added. 0.5-5 µg transfer vector DNA, 1 µg of a eGFP reporter 
plasmid to determine transfection efficiencies (if eGFP was not the cDNA of the 
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transfer vector), and 2 µg of an ecotropic envelope plasmid44 or 5 µg of an RD114/TR 
envelope plasmid (kindly provided by F.-L. Cosset, Lyon, France) were used. In 
addition, 10 µg of a retroviral gag/pol plasmid (M57-DAW) were transfected using the 
calcium phosphate precipitation method. M57 is an MLV gag/pol expression plasmid 
(kindly provided by Harald Wodrich, Montpellier, France) and its derivative M57-DAW 
is devoid of residual overlaps with the transfer vector. When producing lentiviral 
vectors, 5 µg of a Rev plasmid (pRSV-Rev) were co-transfected. For vector pro-
duction of the tet-inducible vector 5 µg of the expression plasmid pPGK.TP, 
harboring the authentic TA with 4C DNA-binding specificity, was co-transfected.  
The medium was changed after 10-12 h. Equal transfection efficiency was controlled 
by FACS analysis. Supernatants containing the viral particles were collected 24-72 h 
after transfection, filtered through a 0.22 µm filter, and stored at -80°C until usage.  
SC-1 cells were transduced by centrifugation for 60 min at 2000 rpm at 32°C in the 
presence of 4 µg/ml protamine sulfate (Sigma-Aldrich). After transduction, cells were 
grown for 4-5 days and subsequently analyzed by flow cytometry and Northern blot. 
Titration of the vector supernatants on SC-1 cells was performed as described 
previously.3 
 
Rhesus monkey primary cells  
Purpose-bred male rhesus monkeys (Macaca mulatta), each weighing 2.5 to 4 kg 
and cynomolgus monkeys (Macaca fascicularis) weighing 4 to 6 kg, aged 2 to 3 
years old, were used. Housing, experiments, and all other conditions were approved 
by an ethics committee in conformity with legal regulations in The Netherlands. 
Purification of CD34+ rhesus cells was performed by positive selection using 
Dynalbeads (Dynal, Oslo, Norway45) Briefly, low-density cells were incubated with an 
IgG2A antibody against CD34 (mAb 561; from G. Gaudernack and T. Egeland, 
Rikshospitalet, Oslo, Norway) covalently linked to rat anti-mouse IgG2A beads. 
CD34+ cells devoid of the CD34-antibody were recovered using polyclonal antibodies 
against the Fab part of the CD34 antibody (Detachebead, Dynal Biotech, Hamburg, 
Germany). Purified CD34+ cells were analyzed by flow cytometry and prestimulated 
at a concentration of 105/ml for 2 days prior transduction in serum-free enriched 
DMEM supplemented with human recombinant growth factors fetal liver tyrosine 
kinase 3-ligand (Flt3-L; 50 ng/ml, kindly provided by Amgen, Thousand Oaks, CA, 
USA), thrombopoietin (rhTPO; 10 ng/ml, kindly provided by Genentech, South San 
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Francisco, CA, USA) and stem cell factor (SCF; 100 ng/ml) as previously 
described.46 
 
Retroviral transduction of Rhesus CD34+ cells 
To enhance the transduction efficiency, Falcon 1008 (35 mm) bacteriological culture 
dishes were coated with recombinant fibronectin fragment CH-296 (Takara Shuzo, 
Otsu, Japan) at a concentration of 10 µg/cm2.47 Before adding the prestimulated 
purified rhesus BM to the fibronectin-coated dishes, the CH-296 fragment was 
preincubated with virus supernatant for 1 hour at 37°C.47 Subsequently, nucleated 
cells were resuspended in the vector-containing supernatant (MOI as indicated in 
Results) supplemented with hematopoietic growth factors (Flt3-L, TPO and SCF) and 
added to the coated and preloaded dishes in a concentration of 1-3 x 105cells/ml. 
Over a period of 2 days, culture supernatant was replaced completely by 
resuspending non-adherent cells into fresh retrovirus supernatant and growth factors. 
After 2 days the cells were harvested, the transduction efficiency was analyzed by 
flow cytometry.  
 
Flow cytometry  
For intracellular staining of MGMT, the Cytofix/Cytoperm Kit (Becton Dickinson, 
Heidelberg, Germany) was used according to manufacturer’s instructions. In brief, at 
least 3 x 105 cells were harvested and washed in phosphate-buffered saline. 
Cytofix/Cytoperm fixative (4% paraformaldehyde: 250 µl) was added for 20 min at 
20°C. Washing with 1 ml Perm/Wash buffer was follow ed by incubation 30 min at 4°C 
with 0.25 µg of a murine anti-MGMT monoclonal antibody (Chemicon, Hampshire, 
UK). After two washing steps with Perm/Wash buffer, 1 µg of a goat-anti-mouse PE-
conjugated secondary antibody (Becton Dickinson) was added for 30 min at 4°C. 
After two additional washing steps, the samples were analyzed in a FACScalibur 
using CellQuest software (Becton Dickinson). A gate was set on a homogenous cell 
population, as determined by scatter characteristics, and 20,000 events were 
monitored. A marker was set to calculate the percentage and mean fluorescence 
intensity of positive cells. For the dual fluorescence assay with eGFP and DsRed 
Express, 2 µg transfer vector, 10 µg M57-DAW, 2 µg ecotropic MLV env were 
transfected into Phoenix-gp cells using the calcium phosphate technique. Three days 
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post transfection, the packaging cells were analyzed by FACS. Compensation of FL-
1 (eGFP) and FL-2 (DsRed Express) was performed using monofluorescent 
constructs. A marker gate was set and the mean fluorescence intensities for eGFP- 
and DsRed Express-positive cells were calculated accordingly.  
 
Northern blot 
Total RNA preparation and Northern blot analysis was performed as described 
before.18 Specific probes (100 ng) corresponding to the PRE fragment, present in the 
respective retroviral and lentiviral vectors and the eGFP cDNA were radiolabeled 
using the DecaLabel DNA labeling kit (Fermentas, St. Leon-Rot, Germany). 
Membranes were washed, sealed, and exposed to X-ray film (Kodak X-Omat-AR, 
Kodak, Stuttgart, Germany) and quantified by Phosphoimager (Amersham, Freiburg, 
Germany) analysis.  
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F. Discussion & Outlook 
The general aim of the present study was the exploitation of modified murine 
leukemia virus-based vectors for targeted and transient cell manipulation. To 
accomplish this, three different vector mutants (∆U5, ∆PBS and aPBS) were 
constructed and tested for their capability to transiently express the gene of interest 
(publication 1). Proof of principle was established with the reversible transfer of 
nucleic acids of the site-directed recombinase Cre into human and mouse fibroblasts 
carrying Cre indicator alleles (Will et al. 2002). Although all three vector mutants were 
clearly disabled in stable gene transfer (up to 10,000-fold reduction compared to the 
wild-type vector), their capability to recombine Cre indicator cells was highly efficient 
(publication 1, Fig. 1 and Fig. 2). Interestingly, the recombination efficacy of the 
aPBS vector mutant was always superior to that seen for the ∆U5 or ∆PBS vector 
mutants (publication 1, Fig. 2A), and was therefore primarily used in the experiments 
contributing to this work.  
 
 
 
Persistent intracellular expression of Cre recombinase is known to have genotoxic 
side effects (Loonstra et al. 2001; Pfeifer et al. 2001; Silver and Livingston 2001) and 
led to the counterselection of cells harboring stable integrated wild-type SF91.nlsCre 
vectors (publication 1, Fig. 2B). However, these side effects were not observed for 
cells treated with aPBS.nlsCre vector particles, strongly arguing for a dose-controlled 
and reversible expression of Cre recombinase in these cells. Further (and to some 
extent more indirect) analysis demonstrated that this type of transient Cre expression 
requires particle assembly, is receptor-mediated (publication 1, Fig. 4) and depends 
on the presence of the packaging signal (Ψ) within the retroviral vector genome 
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(TABLE 1). For that reason we named this technique retroviral particle-mediated 
mRNA transfer (RMT). 
The characterization of RMT particles did not reveal any obvious differences 
concerning genomic RNA content, reverse transcriptase activity or capsid load when 
compared to wild-type particles (publication 2, Table 1 and Fig. 2). In addition, both 
RMT and wild-type retroviral Cre supernatants showed a clear correlation between 
genomic RNA content and the efficacy to recombine Cre indicator cells (biological 
titer) (Fig. 10). 
Replacement of the RMT vector plasmid´s myeloproliferative sarcoma virus (MPSV) 
enhancer-promoter region with sequences from Rous sarcoma virus led to increased 
levels of packageable genomic RNAs in viral producer cells and clearly improved 
RMT in target cells (publication 3, Suppl. Fig. 1). 
 
     
 
To further study the mechanism of RMT, the susceptibility of RMT to cellular 
restriction factors (huTRIM5α and Fv1) and short hairpin RNAs (shRNAs) was 
investigated (publication 2). Both huTRIM5α and to a lesser extent Fv1 were capable 
of effectively restricting RMT (publication 2, Fig. 4 and Fig. 5). Since both factors are 
suggested to interact directly with the retroviral capsid at an early post-entry step 
(Towers et al. 2000; Goff 2004; Stremlau et al. 2004; Passerini et al. 2006), the 
sensitivity of RMT to huTRIM5α and Fv1 supports the hypothesis that the 
phenomenon underlying RMT is particle-mediated rather than due to passive protein 
transfer and/or contamination of retroviral particles by transfected plasmid DNA. 
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Interestingly, the restriction of RMT by huTRIM5α resulted in reduced levels of 
retroviral mRNA in target cells, whereas restriction by Fv1 did not significantly affect 
the incoming retroviral RNA genome (publication 2, Fig. 6A and 6B). Furthermore, 
treatment with the proteasomal inhibitor MG132 partially relieved huTRIM5α-
mediated restriction of RMT (publication 2, Fig. 4D and 4E), which was also reflected 
in partial retroviral mRNA recovery (publication 2, Fig. 6A). Finally, cells ectopically 
expressing shRNAs targeting the retroviral RNA genome inhibited RMT (publication 
2, Fig. 3), also clearly showing that the transferred viral mRNA is the main 
component responsible for the transient expression of foreign proteins via RMT in 
target cells. Thus, these data indicate that as a result of particle remodeling during 
cytoplasmic trafficking, the retroviral mRNA genome may become accessible to 
ribosomes and serve as a translation template if it is not undergoing reverse 
transcription (Fig. 11). 
 
1. RMT in comparison to current transient expression methods:  
Advantages and limitations 
The present study introduces RMT as a potential tool for the transient and reversible 
expression of proteins in target cells. As demonstrated for nlsCre, we showed that 
this type of transient expression method was equally efficient, but did not show any 
cytotoxic side effects in human or mouse fibroblasts when compared to the 
integrating vectors. Noteworthy, this new mode of particle-mediated mRNA transfer 
does not lead to stable integration events, as observed for lentiviral vectors with 
blocked integrase activity (publication 2, Fig. 1C).  
In side by side comparison with alternative transient expression methods, such as 
physicochemical transfection (e.g. lipofection) of transgene expression plasmids or 
the use of adenoviral vectors, RMT was superior for the transient expression of 
nlsCre in Cre indicator cells (publication 1, Suppl. Fig. 2). Thus, in contrast to RMT, 
delivery of nlsCre via episomal adenoviral vectors caused counterselection of cells 
due to persistent Cre expression similar to the integrating gammaretroviral nlsCre 
vector. Furthermore, cells which were physicochemically transfected with an nlsCre 
expression plasmid were not significantly counterselected over time, but showed a 
high mortality rate early after transfection, probably due to the transfection reagent 
(Lipofectamine 2000, Invitrogen). Therefore, RMT represents a dose-controlled and 
non-cytotoxic technique which facilitates cytoplasmic mRNA delivery into a target cell 
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by utilization of all non-cytopathic properties supporting efficient cell entry and 
cytoplasmic trafficking. 
 
 
 
Since we could show that the entry of RMT particles into cells is receptor-mediated 
and depends on the type of the chosen viral envelope protein (publication 1, Fig. 4), 
specific pseudotyping of RMT particles would allow targeting of distinct cells in a 
mixed population. For example, measles virus, which has two types of glycoproteins, 
the hemagglutinin (H) protein responsible for receptor recognition, and the fusion (F) 
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protein which mediates membrane fusion, can be efficiently retargeted by mutating 
the H protein binding sites for its native receptors and fusing single-chain antibody 
fragments to its ectodomain (Nakamura et al. 2005). In a more recent study, the 
successful cell entry targeting of lentiviral vectors through pseudotyping with 
engineered measles glycoproteins was shown (S. Funke et al., American Society of 
Gene Therapy´s (ASGT), 10th annual meeting, 2007). Thus, pseudotyping of RMT 
particles using the envelope proteins of measles virus might also be promising for 
targeted and reversible manipulation of cells. 
However, RMT also has limitations. Taking into consideration that RMT-mediated 
transient expression of proteins is low and only present for a short time span (if 
compared to integrating or episomal retroviral/ lentiviral vectors; publication 2, Fig. 1), 
the protein levels might be not sufficient for applications which require high 
expression levels to show a phenotypic effect. However, one way of increasing the 
intensity and duration of RMT would be to administer the viral particles repetitively. In 
addition, manipulation of the retroviral disassembly process might be a further 
possibility to improve RMT. Furthermore, RMT vector plasmids containing a 5’ RSV 
promoter (see publication 3, Suppl. Fig. 1) or a wPRE element (compare publication 
1, Fig. 1C to publication 2, Fig. 1B) increased RMT titers by more efficient viral 
mRNA load of particles in packaging cells, and thus transgene expression in target 
cells. Thus, it might be reasonable that combination of both elements on the same 
vector plasmid will lead to a further improvement of RMT. 
As shown in this study, RMT can be inhibited by cellular restriction factors and 
shRNAs (publication 2, Fig. 3, 4 and 5). This might also be the case for other forms of 
innate immunity. Thus, potential recognition of retroviral proteins and/or RNA 
genomes by toll-like receptors or cytoplasmic helicases, such as RIG-I (retinoic acid-
inducible gene I) or MDA5 (melanoma-differentiation-associated gene 5), may also 
impair RMT (Yoneyama et al. 2004; Akira et al. 2006; West et al. 2006). However, in 
case of huTRIM5α restriction, inhibition of RMT can be almost completely released 
by blocking the proteasome (publication 2, Fig. 4D). This might also be true for other 
unknown cellular restriction factors, as has been demonstrated by the lab of Luigi 
Naldini. The authors of this paper could show that proteasome inhibition improved 
stable lentiviral gene transfer into hematopoietic stem cells (Santoni de Sio et al. 
2006). However, proteasome inhibitors are known to be cytotoxic and care must be 
taken regarding dose concentration and duration. Importantly, restriction by 
huTRIM5α can be circumvented by choosing NB-tropic (from MoMLV) or B-tropic 
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versions of MLV gag for particle formation, or in the case of lentiviral vectors, gag 
sequences derived from HIV-1. 
Due to low expression levels of RMT, its administration in vivo might require more 
than one application to show the desired phenotype. Although it has been shown that 
retroviruses – in contrast to adenoviruses – are relative weak immunogens (Jooss 
and Chirmule 2003; Thomas et al. 2003; Dalba et al. 2007), the development of 
innate as well as adaptive immune responses has to be considered. In addition, as 
shown for EGFP and β-galactosidase, the nature of the transgene may also induce 
immunity (Stripecke et al. 1999; Jooss and Chirmule 2003; Mian et al. 2005). 
However, the degree to which viral vectors induce harmful immune-mediated and 
inflammatory responses depends upon the amount of antigens presented and must 
exceed a certain threshold (Thomas et al. 2001; Thomas et al. 2003). Due to low and 
short-term expression levels of RMT, this potential risk might be negligible, but needs 
to be more precisely clarified. 
 
2. What makes the aPBS mutant superior to the ∆PBS and ∆U5 
mutants? 
To establish a murine leukemia virus-based gammaretroviral vector system that 
inhibits stable gene transfer, three different vector mutants were generated (aPBS, 
∆PBS and ∆U5, publication 1, Fig. 1A). These vectors were tested for their potential 
to transiently deliver the site-directed recombinase Cre into Cre indicator cells. The 
vector aPBS contains an artificial PBS that was designed not to match any naturally 
occuring tRNA molecule (Lund et al. 1997), whereas the vector ∆PBS completely 
lacks the 18 base pairs being necessary for primer binding. Thus, both vector 
mutants cannot prime RT and are disabled in forming proviral DNA. In contrast, 
vector ∆U5 contains all elements required for reverse transcription into double-
stranded DNA, but lacks the att recognition motif of the retroviral integrase (Basu and 
Varmus 1990), along with flanking sequences of the U5 region. The efficacy of the 
aPBS vector mutant to recombine Cre indicator cells was found to be superior to that 
seen for ∆PBS or ∆U5 mutants (publication 1, Fig. 2A). Interestingly, although the 
∆U5 mutant was expected to result in high recombination efficiencies (formation of 
extrachromosomal retroviral DNA from which nlsCre is transiently expressed over a 
distinct time period), its recombination efficacy was the lowest when compared to 
aPBS and ∆PBS vector mutants. How can this be explained? A recent publication 
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from our laboratory investigated the role of sequences upstream of the 5´ splice site 
(SD) in MLV alternative splice regulation (Kraunus et al. 2006). Detailed analysis of 
the first untranslated exon showed that the primer binding site activates splicing, 
whereas flanking sequences either downstream or upstream of the primer binding 
site are inhibitory. Retroviruses usually exhibit a well-balanced expression of their 
full-length genomic mRNA and their spliced env mRNA variant and thereby ensure 
equal expression of structural and enzymatic proteins for the generation of new virus 
progeny. However, deletion of the 5´ U5 region within murine leukemia-based 
gammaretroviral EGFP vectors (whose splicing pattern is comparable to wild-type 
MLV) strongly enhanced splicing, leading almost exclusively to the accumulation of 
spliced message in the cell cytoplasm (Kraunus et al. 2006). Since the unspliced 
genomic retroviral mRNA is used not only for the production of Gag and Gag/Pol 
precursor proteins, but also represents the packageable retroviral RNA genome, the 
shift to more spliced RNA also results in a greatly decreased titer. In addition, 
deletion of the 5´ U5 region tremendously impairs translational utilization and reduces 
the mean fluorescence intensity of EGFP by 80% when compared with the wild-type 
EGFP vector (Kraunus et al. 2006). Thus, the decrease in titer and impaired 
translational utilization could both contribute to the unexpected low recombination 
efficacy of the ∆U5 mutant. Furthermore, it was shown for avian sarcoma virus 
(ASV), Rous sarcoma virus (RSV) and HIV-1 that sequences within the 5´ U5 region 
are important for primer binding and reverse transcription initiation (Aiyar et al. 1992; 
Morris and Leis 1999; Beerens et al. 2000a; Beerens et al. 2000b; Beerens et al. 
2001; Morris et al. 2002). As this might be also the case for MLV, the impairment of 
reverse transcription could be an additional reason for the poor performance of the 
∆U5 mutant. To further improve the technology of this type of nonintegrating 
extrachromosomal gammaretroviral vector, it might be advisable to introduce only 
mutations that are limited to the att sequences (Nightingale et al. 2006), thereby 
possibly avoiding alterations in splicing ratio, translational utilization and reverse 
transcription. Another step towards episomal retroviral vectors would be the use of 
integrase-mutated (e.g. in the DDE motif of the integrase core domain) 
gammaretroviral vector particles (Philpott and Thrasher 2007) and/or the application 
of integrase inhibitors (e.g. raltegravir). 
Compared to the aPBS variant, the ∆PBS mutant also showed lower nlsCre 
recombination efficacy. The first untranslated exon of MLV is highly structured and 
forms, with U5 and 5’ leader sequences, two stem-loop RNA structures which are 
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separated by the unpaired primer binding site sequences (Mougel et al. 1993). The 
deletion of the primer binding site, as determined by an RNA folding prediction 
program (MFOLD) (Zuker 1989), results in fusion of the two separated stems to an 
elongated, more stabilized RNA stem loop structure (Kraunus et al. 2006) and 
therefore could potentially affect the ribosomal scanning mechanism.  
In contrast to the ∆PBS and ∆U5 mutants, the aPBS mutant demonstrated a similar 
splicing pattern and no loss of translatability as compared to wild-type vectors 
(publication 3, Suppl. Fig.1). Interestingly, western blot analysis of equally transfected 
cells showed even higher translatability of the aPBS vector mutant as compared to 
wild-type vector (publication 3, Suppl. Fig. 1B), probably due to the absence of a 
bound primer (see also below). 
Taken together, the aPBS vector mutant is clearly superior to the other tested 
variants and is the preferred vector construct to achieve RMT. Furthermore, it also 
has the advantage that one and the same construct can be used for RMT or the 
generation of integrating retroviral vectors depending on the co-transfection of the 
artificial tRNA that matches aPBS in packaging cells (Lund et al. 1997). 
 
3. Translation or reverse transcription? Two potential pathways 
for retroviral mRNAs after cell entry 
The reverse transcription process is proposed to begin immediately after entry during 
uncoating of the virion core in the cytoplasm (Telesnitsky and Goff 1997). Similary to 
cellular mRNA, the encapsidated RNA genome of retroviruses harbors a 5´ Cap 
structure and a 3´ PolyA-tail. Thus, in addition to reverse transcription, retroviral 
genomes theoretically represent a template for translation.  
The supplementary figure 3 of publication 1 shows the susceptibility of RMT to the 
reverse transcription inhibitor Azidodeoxythymidine (AZT or zidovudine). AZT is a 
nucleoside analog that acts as a chain terminator if incorporated into DNA because 
the deoxyribose 3´OH residue is replaced by an azido (N3) group. Since retroviral 
reverse transcriptases lack a proof-reading activity, which is reflected by low DNA 
synthesis accuracy (Preston et al. 1988; Goodenow et al. 1989), incorporation of AZT 
into the growing DNA chain results in an irreversible block of reverse transcription. 
In this experiment, SC-1 derived mouse Cre indicator cells were infected with either 
RT-deficient RMT (aPBS.nlsCre) or intact wild-type (SF91.nlsCre) retroviral particles 
in the presence of different AZT concentrations. The recombination efficiencies were 
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determined via FACS analysis three days post transduction. SC-1 cells transduced 
with wild-type SF91.EGFP particles at the same AZT concentrations served as 
internal controls for the efficacy of AZT to block reverse transcription. FACS analysis 
of SF91.EGFP treated SC-1 cells 3 days post transduction revealed that an AZT 
concentration of 5 µM was sufficient to efficiently inhibit stable EGFP transfer. As 
expected, nls.Cre encoding RMT particles (aPBS.nlsCre) were completely insensitive 
to AZT and their efficacy to recombine Cre indicator cells was not even impaired by 
AZT concentrations up to 100 µM. In contrast, the recombination efficiency of wild-
type SF91.nlsCre particles in the presence of AZT was reduced by up to 50%. 
Interestingly, although 5 µM AZT efficiently inhibited stable EGFP transfer of 
SF91.EGFP particles in SC-1 cells, the efficacy of wild-type SF91.nlsCre particles to 
recombine Cre indicator cells was not completely abolished or even decreased at this 
or higher AZT concentrations. These data strongly argue for the presence of AZT-
insensitive, translatable wild-type retroviral RNA genomes within incoming particles 
that led to transient nlsCre expression early after entry. Indeed, at early timepoints 
(5-24 hrs post infection), wild-type particles of SF91.EGFP also showed transient 
EGFP expression in the presence of AZT, but at a lower intensity than the 
corresponding RMT particles (data not shown). These data imply the possibility that 
two types of RNA exist within wild-type particles (vectors SF91.nlsCre or 
SF91.EGFP): translatable, AZT-insensitive and non-translatable, AZT-sensitive 
RNAs. Interestingly, an RMT particle (vector aPBS.nlsCre), complemented by the 
corresponding artificial tRNA (Lund et al. 1997) had a phenotype similar to wild-type 
in the presence of AZT (own observation, data not shown).  
Noteworthy, in the absence of AZT we observed equally increasing EGFP expression 
until 13 hrs after exposure for both SF91.EGFP and aPBS.EGFP vectors (publication 
1, Fig. 1; publication 2, Fig. 1). Since reverse transcription of wild-type particles is  
generally not completed before 8 to 12 h after viral penetration (Telesnitsky and Goff 
1997), one can probably exclude de novo synthesized RNA as the underlying cause 
of GFP expression in the early hours of infection. These data indicate that reverse 
transcription competent particles also harbor translatable genomic mRNA.  
All data taken together, it is tempting to speculate that translatability of the retroviral 
mRNA depends upon the absence of a bound tRNA and/or lack of reverse 
transcription. This would argue for potentially competing pathways (translation vs. 
reverse transcription) for the fate of the retroviral mRNA. In addition, RMT vectors 
(harboring the aPBS) transiently expressed in equally transfected packaging cells 
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(verified by co-transfection of an EGFP expression plasmid, data not shown) 
produced higher transgene protein levels than their corresponding wild-type 
derivatives (publication 3, Suppl. Fig. 1B), further supporting the hypothesis that a 
bound tRNA primer may impede translation. However, further and more extensive 
experiments are needed to address this question. 
 
4. By-product or necessity? Biological purpose of RMT for the 
retroviral life cycle 
We have shown that wild-type vector genomes of incoming retroviral particles may 
also become accessible to ribosomes, leading to a transient transgene expression 
early after entry (publication 1, Fig. 1C and Suppl. Fig. 3; publication 2, Fig. 1C). 
However, this type of RMT is not as efficient as that seen for aPBS vector mutants, 
probably due to viral reverse transcriptase and cellular translation factors competing 
for the same template. There are two possible explanations why RMT can also be 
observed during infection with wild-type particles. First, RMT is a by-product during 
infection, and is mediated by RT-defective particles releasing their RNA genomes for 
translation after disassembly (defective particle hypothesis). However, the 
recombination efficiency of the AZT blocked wild-type virus (SF91.nlsCre) (i.e. the 
RMT proportion) always corresponds to approximately 50% of the value achieved in 
the absence of AZT, independent of the MOI (multiplicity of infections) and the 
retroviral preparation. This stoichiometry was observed in multiple independent 
experiments and for several virus preparations (even for aPBS.nlsCre complemented 
with the artificial corresponding tRNA). This argues against the defective particle 
hypothesis. A second explanation would be that RMT of wild-type particles could 
have a biological purpose and may be necessary for the retroviral life cycle at early 
or late post-entry phases (necessity hypothesis). From an evolutionary perspective, 
the latter would presuppose that the viral genomic RNA necessary for RMT as well 
as reverse transcription originates from a single particle. Interestingly, despite the 
fact that two genomes are encapsidated within an infectious retroviral particle, only 
one provirus is detected after infection with single virions (Hu et al. 1990; Hu and 
Temin 1990). Based on this phenomenon, retrovirions are considered pseudodiploid 
in character. Currently, one popular notion is that the availability of two RNA 
templates during reverse transcription can help retroviruses survive extensive 
damage to their genomes, by intermolecular switching of the RNA templates if 
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necessary (Coffin 1979). Indeed, intermolecular transfer of minus strand strong stop 
DNA (minus strand transfer) and/or plus strand strong stop DNA (plus strand 
transfer) has been observed during reverse transcription (Yu et al. 1998; van Wamel 
and Berkhout 1998), presumably contributing to the preservation of the retroviral 
genetic information (Coffin 1979) as well as dispersing useful mutations and thereby 
promoting viral evolution (Katz and Skalka 1990; Temin 1991). However, only one 
proviral DNA is formed as a result of one infection event and intermolecular minus or 
plus strand transfer has been shown not to be essential for successful reverse 
transcription (Jones et al. 1994). What happens to the RNA genome which is not 
reverse transcribed? The data of the present study suggest that the second RNA 
genome may serve as a template for translation. If both processes (translation and 
reverse transcription) take place in close proximity, one could further speculate that 
translation of the genome which does not undergo reverse transcription has a 
biological purpose and leads to the expression of viral proteins or the recruitment of 
cellular proteins that are necessary for a successful completion of the infectious life 
cycle of retroviruses. 
 
5. Do eukaryotic translation initiation factors assist during 
reverse transcription? 
Reverse transcription is proposed to begin subsequently after entry into the 
cytoplasm. However, there are reports that reverse transcription can initiate in 
extracellular virions, but at rather low frequencies. It was shown that not more than 1 
in 1000 particles possess minus strand strong-stop DNA (Lori et al. 1992; Trono 
1992; Zhang et al. 1993), therefore the significance of this in infection processes is 
questionable. These observations are be supported by our data, where the presence 
of AZT during packaging of wild-type vector particles had no significant influence on 
transduction efficiencies of target cells (data not shown). Currently, it is thought that 
the most limiting factor of reverse transcription is the availability of dNTPs, a resource 
which is found in large quantities in the cytoplasm of an infected cell. This view is 
based on the observations that reverse transcription proceeds poorly in quiescent 
cells where intracellular dNTP concentrations are low (Zack et al. 1990; Zack et al. 
1992), and simply increasing the concentration of dNTPs permits accumulation of 
full-length retroviral DNA (O'Brien et al. 1994). In addition, it is possible that the size 
and structure of extracellular virions preclude significant DNA synthesis before 
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cytoplasmic entry, so that core disassembly may be necessary for reverse 
transcription to occur.  
In this study, RMT was also observed in cells infected with wild-type retroviral 
particles (publication 1, Fig. 1C and Suppl. Fig. 3; publication 2, Fig. 1). This implies, 
as already discussed, that the capped and polyadenylated wild-type genome is 
accessible to ribosomes for translation. However, the translatability of retroviral 
genomic mRNAs seems to depend on the absence of a bound primer and/or lack of 
reverse transcription, hence indicating that reverse transcription and translation of 
retroviral wild-type genomes are two competing processes. Furthermore, the 
observation that approximately 50% of retroviral RNA genomes (publication 1, Suppl. 
Fig. 3) (e.g. one out of two RNA genomes per virion) is capable of RMT within 
SF91.nlsCre wild-type particles, argues against RT-defective particles being 
responsible for RMT. If the template for RMT and reverse transcription may originate 
from the same wild-type particle, it is tempting to speculate that the disassembled 
particles become accessible to translational initiation factors, thereby causing a 
competition of translation and initiation of reverse transcription (as already discussed 
above). Noteworthy, during translational initiation, eIF4G (eukaryotic initiation factor 
4G) bridges the cap binding protein eIF4E with the polyA binding protein (PABP) and 
circularizes the mRNA to facilitate translation (Fig. 12) (Gebauer and Hentze 2004). 
This process brings the 3’ UTR in close proximity to the 5’ end of the mRNA (Wells et 
al. 1998). Interestingly, this close proximity of both mRNA ends - induced by 
translational initation factors – might also be beneficial during reverse transcription 
and could theoretically assist in successful plus and minus strand transfer (Fig. 5). Of 
note, the PABP has been found in purified retroviral vector particles by proteomic 
analysis (Segura et al. 2008). This discussion points the way to further experiments 
addressing the “necessity hypothesis” in that, besides the availability of dNTPs, 
eukaryotic translational initiation factors might be involved in successful retroviral 
reverse transcription. 
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6. The inhibition of RMT via endogenously expressed human 
TRIM5α is caused by mRNA degradation 
The human cytoplasmic restriction factor TRIM5α blocks N-tropic MLV at an early 
post-entry step and prevents the accumlation of reverse transcription products in 
infected cells (Himathongkham and Luciw 1996; Towers et al. 2000; Cowan et al. 
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2002; Besnier et al. 2003; Stremlau et al. 2004; Passerini et al. 2006). The main 
retroviral determinant which confers susceptibility to huTRIM5α is located within the 
N-tropic retroviral capsid protein (arginine 110) and is suggested to be recognized by 
the C-terminal PRYSPRY domain of huTRIM5α (Towers et al. 2000; Perron et al. 
2004).  
Although extensive studies have been persued over the last years, less is known 
about the exact mechanism by which TRIM5α proteins restrict retroviral infection 
after capsid recognition. One study supports the idea that TRIM5α intervenes with 
the normal uncoating step of the viral capsid, and that this leads to an accelerated 
disassembly of the capsid structure, leaving the retroviral RNA genome unprotected 
(Perron et al. 2004; Perron et al. 2007). In addition, these authors argue that ubiquitin 
ligation, proteasome degradation, and/or massive degradation of the viral core are 
not essential components of TRIM5α restriction (Perron et al. 2007). Moreover, N-
tropic MLV infection was efficiently blocked by huTRIM5α in a Chinese hamster E36 
cell line expressing a temperature sensitive E1 ubiquitin ligase, even at the 
nonpermissive temperature (Perez-Caballero et al. 2005b). However, the laboratory 
of Thomas J. Hope found that proteasome inhibition abrogates the ability of human 
and rhesus TRIM5α proteins to prevent the accumulation of RT products, but that this 
does not relieve the ability of TRIM5α proteins to restrict viral infection (Anderson et 
al. 2006; Wu et al. 2006). A more recent study by the same laboratory showed that 
proteasome inhibition prevents the clearance of HIV-1 viral complexes from the 
cytoplasm, leading to the stable sequestration of these complexes in cytoplasmic 
bodies (Campbell et al. 2008). 
In the present study, the susceptibility of reverse transcription-deficient aPBS (RMT) 
vector particles to endogenously expressed huTRIM5α was investigated (publication 
2, Fig. 4 and 6). We found that N-tropic RMT vector particles are sensitive to 
huTRIM5α and that restriction is accompanied by a clear loss of retroviral genomic 
mRNA as well as an accelerated degradation of retroviral capsid proteins in 
restrictive human Cre indicator cells. Furthermore, proteasome inhibition with MG132 
almost completely abrogates huTRIM5α-mediated restriction of RMT vector particles 
and is reflected in the partial recovery of retroviral mRNA genomes. Since transient 
protein expression via RMT depends not only on the accessibility but also the 
availability (amount) of translatable retroviral mRNA genomes within the cytoplasm of 
target cells, the data obtained with MG132 indicate that the main limiting factor during 
restriction of RMT by endogenous huTRIM5α is the loss of retroviral mRNA genomes 
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rather than their reduced accessibility (trapping in huTRIM5α cytoplasmic bodies). 
Interestingly, in contrast to human Cre indicator cells, the degradation of retroviral 
genomic mRNA derived from N-tropic aPBS.nlsCre particles is 5 times less 
pronounced in feline Cre indicator cells ectopically expressing huTRIM5α. However, 
western blot analysis of these cells still showed accelerated degradation of N-tropic 
capsid proteins. The result of these observations is an approximately 2 times higher 
recombination efficacy of N-tropic aPBS.nlsCre particles when compared to their B-
tropic counterparts in feline Cre indicator cells. Interestingly, MG132 could not further 
improve N-tropic-mediated RMT in this cellular background (unpublished 
observations, data not shown). These data further support the hypothesis that the 
observed inhibition of N-tropic RMT particles in human Cre indicator cells 
(endogenously expressing huTRIM5α) is mainly due to subsequent degradation of 
the retroviral RNA genomes. Furthermore, the different behavior of N-tropic RMT 
particles in human and feline fibroblasts expressing huTRIM5α may argue for the 
existence of one or multiple cellular cofactors which are responsible for the 
proteasome dependent degradation of retroviral RNA genomes in human cells. 
The current understanding of TRIM5α-mediated restriction does not include the 
targeted degradation of retroviral RNA genomes derived from restricted wild-type 
(RT-competent) particles (Chatterji et al. 2006). However, the data of the present 
study revealed that RNA genomes from N-tropic particles underlie targeted and 
proteasome dependent degradation in human cells endogenously expressing 
TRIM5α. The fact that human and rhesus TRIM5α prevent accumulation of retroviral 
RT products and that proteasome inhibition abrogates this ability (Anderson et al. 
2006; Wu et al. 2006), suggests that inhibition of RT is simply a consequence of 
retroviral RNA genome degradation.  
Combining results from our laboratory with those published by others led us to 
propose the following model (Fig. 13). Shortly after entry, the capsid of an incoming 
N-tropic retroviral RMT particle is recognized by huTRIM5α. Subsequently, the 
particle becomes sequestered in huTRIM5α cytoplasmic bodies, where, potentially, 
accelerated uncoating and/or degradation of the retroviral capsid occurs. When 
endogenously expressed in human fibroblasts, huTRIM5α leads to a proteasome 
dependent degradation (probably triggered by a cofactor X) of the retroviral genomic 
RNA, resulting in inhibition of RMT. In contrast, ectopically expressed huTRIM5α in 
feline fibroblasts causes only moderate decreases in genomic RNA levels, as 
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reflected in higher transient expression levels when compared to the unrestricted 
counterpart.  
 
 
 
7. Outlook and implications for future applications 
The present study introduces RMT as an engineered gammaretroviral vector system, 
which allows the reversible manipulation of cells. The transferred retroviral mRNA – 
packaged into retroviral particles – follows the fate of retroviral entry, and delivers the 
mRNA genome encoding the gene of interest as a template for translation in the 
cytoplasm of target cells. Since retroviral entry is receptor-mediated, distinct cell 
populations can be targeted for dose-controlled transient protein expression.  
Noteworthy, gene transfer via RMT prevents the problem of insertional mutagenesis, 
the dysregulation of neighboring genes by integration of the vector cassette into the 
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host cell chromatin (Li et al. 2002; Hacein-Bey-Abina et al. 2003a; Hacein-Bey-Abina 
et al. 2003b). Therefore, retroviral non-integrating and transient gene transfer 
approaches, such as episomal DNA (e.g. 2-LTR circles initiated by integrase-
deficient lentiviral vectors) and the transfer of translatable mRNA are desirable and 
represent useful alternatives to the conventionally used integrating vector systems. 
Generally, RMT might be particularly useful and of relevance in applications where 
relatively low and transient expression of proteins confers striking biological effects. 
One interesting area of application would be to modify cell fate by transiently 
introducing proteins that lead to defined changes in cell behavior. Examples are the 
expression of receptors involved in homing of circulating stem cells, transcription 
factors or other cellular proteins regulating cell expansion and differentiation, and 
recombinases (e.g. nlsCre) or integrases for targeted genetic interventions. The 
following paragraphs will give a few examples of possible scenarios. 
The ectopic expression of the homeobox transcription factors HoxB4 (Antonchuk et 
al. 2002) or Nup-HoxA10 fusion protein (Pineault et al. 2005) are useful tools for 
expansion of hematopoietic stem cells (HSC) in vitro. However, their stable ectopic 
expression can drastically alter lineage repopulation ability (Schiedlmeier et al. 2003) 
in vivo and even contribute to leukemogenesis (Zhang et al. 2008). Thus, HoxB4 
expression via RMT would be a safer alternative.  
Recently, transcription factors (Oct3/4, Sox2, Klf4 and optionally also c-Myc) needed 
for genetic reprogramming of somatic (differentiated) cells to an embryonic stem cell-
like state (so called induced pluripotent stem cells, iPS) have been identified 
(Takahashi and Yamanaka 2006; Meissner et al. 2007). Induction of pluripotent stem 
cells was demonstrated from murine and human fibroblasts. Interestingly, the four 
factors necessary for reprogramming the fibroblasts into iPS cells only had to be 
expressed for 10-12 days (Brambrink et al. 2008; Stadtfeld et al. 2008). Since the 
shutdown of the three (four) introduced factors after 10-12 days is a prerequisite for 
normal cell differentiation (Brambrink et al. 2008), RMT could be a useful tool for 
reprogramming differentiated cells to iPS cells.  
A third example may be the use of RMT for cancer gene therapy. The transient 
expression of apoptosis inducing proteins in cancer cells, such as Bax (BCL-2-
associated X protein) and Bak (BCL-2-antagonist/killer-1), which are involved in 
mitochondrial fragmentation and thereby release of apoptogenic (cytochrome C) and 
apoptosis inducing factors (AIF), could be sufficient to trigger cell death (Tsujimoto 
1998; Kuwana et al. 2005). An alternative would be the transient expression of 
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cytotoxic proteins, such as diphtheria toxin A or plant-derived toxins Aralin (from 
Aralia elata) or Ricin (from Ricinus communis), which are known to efficiently 
inactivate protein synthesis, thereby causing cell death (Olsnes 1978; Maxwell et al. 
1986; Lord et al. 1994; Tomatsu et al. 2003; Michl and Gress 2004).  
Provided that RMT-mediated transgene expression levels are sufficient to induce 
adequate immune responses, it might be feasible to use RMT particles as either 
prophylactic or therapeutic tools for vaccination against infectious diseases or 
cancer. So far, conditionally replicating vectors (replicating properties are under the 
control of a tetracycline-regulated promoter) and genome free particles (so-called 
virus-like particles, VLPs) have been developed for different types of protective 
cellular immunity (Dalba et al. 2007). Whereas conditionally replicating vectors still 
suffer from some level of leakiness (intrinsic activity refractory to doxycycline) and 
thereby impair safety (Pluta et al. 2005), VLPs have demonstrated safe and efficient 
induction of humoral and cellular immune responses in animal studies (Boisgerault et 
al. 2002) as well as in phase II and III clinical trials (Harper et al. 2004; Villa 2006). 
Thus, the expression of specific antigens via RMT in dendritic or other antigen 
presenting cells could be an interesting tool for vaccination. 
Besides this multitude of practical implications associated with our discovery of the 
RMT process, this thesis also introduces RMT as a novel tool to obtain insights into 
unsolved processes of the retroviral life cycle. Here, the interaction of cellular host 
factors (huTRIM5α, Fv1) with RMT particles has been studied. In the case of 
huTRIM5α-mediated restriction, our data has led to a more complete picture of 
huTRIM5α-mediated restriction of N-tropic gammaretroviral particles. Therefore, RMT 
might be an interesting tool to study other retrovirus-host interactions, especially 
those that are upstream and independent of reverse transcription (e.g. retroviral 
disassembly, RTC formation). The gain of further insights into retrovirus-host 
interactions and/or the retroviral life cycle will allow the development of new 
antiretroviral therapies. Furthermore, the more detailed understanding of processes 
within the retroviral life cycle can be used for the enhancement of retroviral or 
lentiviral vector technologies. Conversely, further and deeper insights into retroviral 
entry and disassembly mechanisms may allow further improvement of RMT, leading 
to higher protein expression levels in target cells.  
In conclusion, RMT vector particles hold great promise for applications in which low 
and transient expression of proteins achieves striking biological effects, and are 
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useful tools to decipher retrovirus-host interactions early after entry before proviral 
DNA synthesis.  
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